<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">EJNMMI Res</journal-id>
<journal-id journal-id-type="iso-abbrev">EJNMMI Res</journal-id>
<journal-title-group>
<journal-title>EJNMMI Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2191-219X</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32725278</article-id>
<article-id pub-id-type="pmc">7387399</article-id>
<article-id pub-id-type="publisher-id">673</article-id>
<article-id pub-id-type="doi">10.1186/s13550-020-00673-7</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Baart</surname>
<given-names>V. M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Houvast</surname>
<given-names>R. D.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Geus-Oei</surname>
<given-names>L. F.</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quax</surname>
<given-names>P. H. A.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kuppen</surname>
<given-names>P. J. K.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vahrmeijer</surname>
<given-names>A. L.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4337-2758</contrib-id>
<name>
<surname>Sier</surname>
<given-names>C. F. M.</given-names>
</name>
<address>
<email>c.f.m.sier@lumc.nl</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.10419.3d</institution-id><institution-id institution-id-type="ISNI">0000000089452978</institution-id><institution>Department of Surgery, </institution><institution>Leiden University Medical Center, </institution></institution-wrap>Albinusdreef 2, 2333 ZA Leiden, The Netherlands </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.10419.3d</institution-id><institution-id institution-id-type="ISNI">0000000089452978</institution-id><institution>Department of Radiology, Section of Nuclear Medicine, </institution><institution>Leiden University Medical Center, </institution></institution-wrap>Leiden, The Netherlands </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.6214.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0399 8953</institution-id><institution>Biomedical Photonic Imaging Group, </institution><institution>University of Twente, </institution></institution-wrap>Enschede, The Netherlands </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.470625.2</institution-id><institution>Percuros BV, </institution></institution-wrap>Leiden, The Netherlands </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>28</day>
<month>7</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>7</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>10</volume>
<elocation-id>87</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>7</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">The urokinase plasminogen activator receptor (uPAR) plays a multifaceted role in almost any process where migration of cells and tissue-remodeling is involved such as inflammation, but also in diseases as arthritis and cancer. Normally, uPAR is absent in healthy tissues. By its carefully orchestrated interaction with the protease urokinase plasminogen activator and its inhibitor (plasminogen activator inhibitor-1), uPAR localizes a cascade of proteolytic activities, enabling (patho)physiologic cell migration. Moreover, via the interaction with a broad range of cell membrane proteins, like vitronectin and various integrins, uPAR plays a significant, but not yet completely understood, role in differentiation and proliferation of cells, affecting also disease progression. The implications of these processes, either for diagnostics or therapeutics, have received much attention in oncology, but only limited beyond. Nonetheless, the role of uPAR in different diseases provides ample opportunity to exploit new applications for targeting. Especially in the fields of oncology, cardiology, rheumatology, neurology, and infectious diseases, uPAR-targeted molecular imaging could offer insights for new directions in diagnosis, surveillance, or treatment options.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Nuclear imaging</kwd>
<kwd>PET</kwd>
<kwd>Image-guided surgery</kwd>
<kwd>uPA</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>H2020 Marie Skłodowska-Curie Actions ()</institution>
</funding-source>
<award-id>872860 - PRISAR2</award-id>
<award-id>857894 - CAST</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par34">Tissue remodeling is pivotal in embryonic development, tissue repair, and numerous pathologies. Temporary degradation of the extracellular matrix (ECM) is a delicate process requiring the careful coordination of proteases, receptors, and cell-signaling molecules where over-degradation can result in osteoarthritis, osteolysis, cardiomyopathy, and invasion/metastasis of tumor cells, and where over-production of the ECM often leads to fibrosis [<xref ref-type="bibr" rid="CR1">1</xref>]. It seems conceivable that monitoring of the process of matrix remodeling offers possibilities for diagnosis, surveillance, and possibly even treatment of the associated diseases. For clinical applications, such as biomedical imaging or therapy, a cell-associated target protein with a central role within the ECM-remodeling process, but with limited expression in healthy tissue, would be helpful in identifying patient groups requiring more intensive monitoring or therapy. Furthermore, molecular imaging enables real-time imaging of pathophysiology, providing novel insights into disease processes that cannot be gathered with current techniques such as post-mortem tissue analysis or with animal models [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p>
<p id="Par35">Inherent to its nature, molecular imaging is fundamentally dependent on identifying appropriate targets that are informative about the underlying pathophysiology of the process studied [<xref ref-type="bibr" rid="CR4">4</xref>]. As targeting different epitopes on the same protein may influence the ability to image specific processes, formal description of the epitope is crucial. Important to realize is that differing epitopes on the same protein can alter the results and consequently, describing the epitope of interest is just as crucial [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, a key competence of targeted imaging is designing the best performing probe for the imaging modality of choice. The choices to be made are extensive and have already been covered in reviews elsewhere [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>].</p>
<p id="Par36">The urokinase plasminogen activator receptor (uPAR) holds a central position in ECM proteolysis, but, next to the proteolytic role, uPAR is also involved in cell-cell and cell-ECM interactions, regulating cell signaling and hereby controlling cell proliferation, differentiation, and migration [<xref ref-type="bibr" rid="CR10">10</xref>]. uPAR is normally hardly found in healthy tissue, but it is present in virtually all human malignancies, associated with disease aggressiveness, allowing tumors to escape their original boundaries [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. As a result, the field of uPAR-based oncological imaging is progressing rapidly and, not surprisingly, various positron-emission tomography (PET)-based molecular imaging clinical trials are currently being conducted for diagnosing aggressive cancers and determining cancer aggressiveness (NCT02755675, NCT02945826, and NCT03307460) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p>
<p id="Par37">The last two decades have revealed that uPAR is not only a central orchestrator in oncology but also in processes ranging from neurology to auto-immune diseases [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Likewise, by unraveling the various (patho)physiological processes uPAR contributes to novel opportunities to diagnose, treat, or monitor diseases have been revealed. The current review aims to identify non-neoplastic diseases where uPAR is of pathophysiological relevance and elaborate on the molecular imaging opportunities this provides.</p>
<sec id="Sec2">
<title>The urokinase plasminogen activator receptor: a central player in an extensive interactome</title>
<p id="Par38">In 1985, uPAR was first identified on monocytes as the cell membrane receptor of the urokinase plasminogen activator (uPA) [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In the following 35 years, uPAR has been identified, although often only expressed transiently, on, among others, fibroblasts, endothelial cells, epithelial cells, and neurons [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Rather than being cell-specific, uPAR expression should be considered as process-specific with all cells being able to express uPAR, but only doing this at very specific events, such as the cell extravasation and migration observed during wound healing (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>). Consequently, most cells at rest have no uPAR on their cell membrane [<xref ref-type="bibr" rid="CR11">11</xref>]. A closer look at uPAR-expressing cells reveals that uPAR is implicated in multiple processes where the balance of this determines the end result (Fig. <xref ref-type="fig" rid="Fig1">1b</xref>).
<fig id="Fig1"><label>Fig. 1</label><caption><p>The urokinase plasminogen activator receptor (uPAR). <bold>a</bold> While usually quiescent in normal tissue, uPAR expression is observed transiently and locally during specific cellular processes such as extravasation and migration by wound healing. <bold>b</bold> At a cellular level, uPAR interacts in a multitude of pathways where the balance of each dictates the end result. <bold>c</bold> uPAR itself is a three domain extracellular structure linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. <bold>d</bold> Classically uPAR functions as receptor for urokinase plasminogen activator (uPA) which subsequently breaks down the extracellular matrix (ECM) via plasminogen activation. <bold>e</bold> Intracellular signaling occurs via other receptors including vitronectin and integrins and can be uPA dependent and independent. <bold>f</bold> Internalization and recycling of uPAR occurs after a uPAR/uPA/PAI-1/LRP-1 complex has formed, which results in the degradation of uPA and PAI-1 and the recycling of uPAR and LRP-1. <bold>g</bold> uPAR can be cleaved at the GPI-anchor and between D1 and D2 resulting in various isoforms of soluble uPAR which can be quantified in the blood. <bold>h</bold> After cleavage of D1, uPAR D2-D3 induces chemotaxis by interacting with formyl peptide receptor-like 1 (FPRL1)</p></caption><graphic id="MO1" xlink:href="13550_2020_673_Fig1_HTML"></graphic></fig></p>
<p id="Par39">To understand how uPAR can play such a diverse and central role, a careful examination of its structure needs to be made. uPAR is a 283 amino acid glycosylphosphatidylinositol (GPI)-anchored membrane protein consisting of three domains (D1-D3) linked by two flexible hinges (Fig. <xref ref-type="fig" rid="Fig1">1c</xref>) [<xref ref-type="bibr" rid="CR20">20</xref>]. These three domains form a concave surface where uPA can bind [<xref ref-type="bibr" rid="CR21">21</xref>]. Subsequently, uPAR mediates its other, non-proteolytic-related effects via protein interactions on the outer surface. D1 and the hinge region between D1 and D2 are vital for uPAR-vitronectin interactions, whereas various epitopes on D2-D3 interact with integrins, G protein-coupled receptors (GPCRs) and receptor tyrosine kinases like epidermal growth factor receptor, platelet-derived growth factor receptor, and insulin-like growth factor 1 receptor [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. With over 42 interacting proteins described, uPAR forms a central orchestrator of cell proliferation, differentiation, migration, and survival [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p>
<p id="Par40">Classically, the function of uPAR is fairly straightforward. Without intracellular or transmembrane domains, uPAR primarily functions as a receptor for (pro)uPA (Fig. <xref ref-type="fig" rid="Fig1">1d</xref>) [<xref ref-type="bibr" rid="CR24">24</xref>]. uPA is a serine protease that catalyzes the activation of the ubiquitously present plasminogen into plasmin. Active plasmin degrades ECM proteins by itself or via activation of latent matrix metalloproteases (MMPs) [<xref ref-type="bibr" rid="CR25">25</xref>]. Localization of both the inactive form, pro-uPA and active uPA to the cell surface, allows cells to focus extracellular matrix degradation toward the leading edge of the cell [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. However, this classic view of uPAR does not justify the many subtleties present in the uPAR interactome. For instance, the distinct central binding cavity of uPAR and the flexible hinges result in a conformational change after uPA binding that alters the vitronectin binding site, enhancing uPAR-vitronectin interaction on the outer surface of uPAR [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR30">30</xref>]. Vice versa, vitronectin binding to uPAR influences the affinity for uPA [<xref ref-type="bibr" rid="CR31">31</xref>]. Another subtlety of uPAR characteristics lies in the GPI anchoring to the cell, which influences distribution of uPAR toward lipid rafts and subsequently promotes specific protein-protein interactions [<xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR34">34</xref>]. Furthermore, GPI anchorage allows a rapid removal from the cell membrane, allowing a quick turnover and response time.</p>
<p id="Par41">The intracellular signaling pathway initiated by uPAR, either enabled by uPA, with or without vitronectin, is still not entirely understood (Fig. <xref ref-type="fig" rid="Fig1">1e</xref>) [<xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR39">39</xref>]. On neutrophils and macrophages, CD11b/CD18 (MAC1, complement receptor 3 or αMβ2) colocalizes with uPAR and is essential for adhesion, migration, and phagocytosis [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR47">47</xref>]. In combination with the β1 integrin subunit, uPAR promotes differentiation, proliferation, adhesion, of epithelial and other cells and stimulates expression of uPA, uPAR, and MMPs, promoting extracellular proteolysis [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR48">48</xref>–<xref ref-type="bibr" rid="CR54">54</xref>]. Furthermore, β3-uPAR-mediated signaling enhances cell motility and invasion, while β6-uPAR interaction stimulates proliferation and cell differentiation [<xref ref-type="bibr" rid="CR55">55</xref>–<xref ref-type="bibr" rid="CR58">58</xref>].</p>
<p id="Par42">Finally, recycling and cleavage of uPAR play an important role in cell functioning (Fig. <xref ref-type="fig" rid="Fig1">1f</xref>).</p>
<p id="Par43">Plasminogen activator inhibitor-1 (PAI-1) and uPA are internalized for degradation via uPAR and lipoprotein receptor-related protein 1 interaction (LRP1) [<xref ref-type="bibr" rid="CR59">59</xref>–<xref ref-type="bibr" rid="CR61">61</xref>]. uPAR and LRP1 are recycled to the cell membrane ready for new interactions [<xref ref-type="bibr" rid="CR62">62</xref>]. Cleavage of uPAR can occur at two sites: (I) within the GPI anchor by lipases, resulting in soluble uPAR (suPAR) and (II) between D1 and D2 resulting in cleaved uPAR (soluble D1 and soluble or membrane-bound D2-D3) (Fig. <xref ref-type="fig" rid="Fig1">1g</xref>) [<xref ref-type="bibr" rid="CR63">63</xref>]. The exact function of full-length suPAR is unclear but suPAR might function as a scavenger protein for uPA, consequently competitively inhibiting cell surface proteolysis [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Cleavage of D1 unveils an amino acid sequence (amino acids, 88-92) on D2-D3 that is unable to interact with integrins but interacts with GPCR formyl peptide receptor-like 1 (FPRL1), prompting migration (Fig. <xref ref-type="fig" rid="Fig1">1h</xref>) [<xref ref-type="bibr" rid="CR66">66</xref>]. When cleaved, the same D2-D3 epitope induces chemotaxis in FPRL1-expressing cells [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</p>
</sec>
<sec id="Sec3">
<title>uPAR in cardiovascular disease: determining plaque instability in atherosclerosis</title>
<p id="Par44">Although significant improvements have been made in the management of cardiovascular disease, it is still a leading cause of death worldwide [<xref ref-type="bibr" rid="CR69">69</xref>]. The current state-of-art diagnostic techniques, such as angiography or perfusion imaging, can accurately identify stenosis location and luminal occlusion in order to guide revascularization, however, fail to determine risk of rupture [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Identifying these patients is the next challenging frontier in cardiovascular disease research: more than 50% of patients who die suddenly have no evident clinical symptoms and autopsy studies indicate that the majority of myocardial infarctions are caused by non-flow limiting lesions [<xref ref-type="bibr" rid="CR72">72</xref>–<xref ref-type="bibr" rid="CR74">74</xref>]. Based on its mechanistic role, molecular imaging of uPAR expression status might be an alternative and more targeted tool to improve the recognition of atherosclerotic plaques and the risk of rupture.</p>
<p id="Par45">Atherosclerosis is the formation of intimal plaques consisting of two interacting regions: a central core covered by a fibrous cap. Cholesterol filled monocyte-derived macrophage-foam cells form the core whereas the cap consists of vascular smooth muscle cells (VSMCs) that have been recruited from the media [<xref ref-type="bibr" rid="CR75">75</xref>–<xref ref-type="bibr" rid="CR77">77</xref>]. In both regions of the plaques, the urokinase plasminogen activation axis (uPA/uPAR/PAI-1 axis) has been shown pivotal for development and progression of the disease. Monocyte adherence and recruitment toward lesion sites are dependent on uPAR expression, and upon arrival in the lesion, uPA interaction with uPAR has been implicated in the differentiation of monocytes to macrophages, and cholesterol biosynthesis and subsequent lipid uptake (Fig. <xref ref-type="fig" rid="Fig2">2a, b</xref>) [<xref ref-type="bibr" rid="CR78">78</xref>–<xref ref-type="bibr" rid="CR83">83</xref>]. In response to vascular injury, VSMCs undergo a change from a physiological contractile phenotype to the pathological synthetic phenotype, allowing them to migrate, proliferate, and produce extracellular matrix, as found in the caps of atherosclerotic plaques. This process is stimulated by intimal macrophages-derived uPA binding to the uPAR present on VSMCs (Fig. <xref ref-type="fig" rid="Fig2">2c</xref>) [<xref ref-type="bibr" rid="CR84">84</xref>–<xref ref-type="bibr" rid="CR93">93</xref>]. Furthermore, uPAR expression upregulates the calcification of these lesions, although the consequences for plaque stability remain to be clarified [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Overall, many in vitro mechanistic studies demonstrate the enhanced presence and pivotal role of uPAR in atherogenesis and negative (inward) remodeling [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. These data are supported by various immunohistochemical studies on patients, which have clearly localized uPAR overexpression to atherosclerosis: while normal arterial tissue is negative for uPAR, intensely positive stained lymphocytes, macrophages, and intimal smooth muscle cells are found in atherosclerotic lesions and atheroma’s [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR97">97</xref>–<xref ref-type="bibr" rid="CR101">101</xref>]. Likewise, the overexpression of uPAR is confirmed in gene analysis with a 1.5 fold higher uPAR expression in endarterectomies [<xref ref-type="bibr" rid="CR99">99</xref>]. The level of uPAR overexpression has been associated with disease severity and localized uPAR expression is indicative for areas at risk for rupture (Fig. <xref ref-type="fig" rid="Fig2">2d</xref>) [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR102">102</xref>].
<fig id="Fig2"><label>Fig. 2</label><caption><p>uPAR in atherosclerosis. <bold>a</bold> Monocyte extravasation across the endothelium lesions is dependent on uPAR. <bold>b</bold> Upon interaction with uPA these monocytes differentiate into macrophages, eventually resulting in cholesterol filled monocyte-derived macrophages. <bold>c</bold> uPA released from macrophages interacts with uPAR on synthetic smooth muscle cells stimulating their migration. <bold>d</bold> Localized uPAR overexpression in an atherosclerotic plaque increases the risk of rupture. uPAR is represented by the red 3-domain structure as described in Fig. <xref ref-type="fig" rid="Fig1">1</xref> on the cell membrane of uPAR expressing cells and uPA by the green structure in the extracellular matrix and bound to uPAR</p></caption><graphic id="MO2" xlink:href="13550_2020_673_Fig2_HTML"></graphic></fig></p>
<p id="Par46">As uPAR has been implicated in the pathophysiology of atherosclerosis, various studies have attempted to improve disease outcomes by targeting of uPAR to block its function. Viral and non-viral expression vectors, encoding constructs consisting of ATF (the amino-terminal fragment of urokinase with high affinity for uPAR) in combination with inhibitors of the plasminogen pathway like BPTI (bovine pancreas trypsin inhibitor) or of matrix metalloproteinases like TIMP1 (tissue inhibitor of matrix metalloproteinases 1), successfully inhibited neointimal formation, VSMC migration, and vein graft thickening in rodent models and human saphenous vein cultures [<xref ref-type="bibr" rid="CR103">103</xref>–<xref ref-type="bibr" rid="CR106">106</xref>]. Eventually, a construct consisting of all three of these proteins has been shown to lead to the strongest reduction in vein graft thickening in hypercholesterolemic mice [<xref ref-type="bibr" rid="CR107">107</xref>]. While these preclinical studies show evident potential of uPAR as target for atherosclerosis targeting, the concept has not yet been progressed toward a clinical application neither for therapy nor for diagnostic monitoring via molecular targeted imaging.</p>
</sec>
<sec id="Sec4">
<title>uPAR in auto-immune disease: imaging disease activity in rheumatoid arthritis</title>
<p id="Par47">Rheumatoid arthritis (RA) is a chronic inflammatory disease with a lifetime risk of 3.6% for women and 1.7% for men [<xref ref-type="bibr" rid="CR108">108</xref>]. Anatomical imaging techniques, such as conventional radiology, ultrasound, and magnetic resonance imaging, along with clinical criteria, are the standard to diagnose and monitor RA [<xref ref-type="bibr" rid="CR109">109</xref>]. These modalities are able to identify RA as soon as 6-8 weeks after arthritis onset and sometimes even before the first clinical symptoms [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Current research efforts lie in patient stratification according to disease severity and identifying responders to expensive novel biologicals [<xref ref-type="bibr" rid="CR111">111</xref>]. Targeted molecular imaging might offer a solution for the current goals of identifying aggressive disease and treatment potential, providing a more reliable prognosis, evaluating/comparing new therapies, and providing new insights in the pathophysiology of RA [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR112">112</xref>].</p>
<p id="Par48">As RA progresses, the initially sparsely populated articular region becomes infiltrated with immune cells, neutrophils and monocytes/macrophages, fibroblast-like synoviocytes (FLS), and osteoclasts [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]. The interaction of these cells directly with each other and via cytokines has many similarities with locally invasive malignancies, leading to chronic inflammation, and tissue invasion, remodeling, and destruction [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. In the RA microenvironment, FLS acquire the tumor-like characteristic of being able to escape growth limits, enhance migration and invasion, and to prompt angiogenesis [<xref ref-type="bibr" rid="CR16">16</xref>]. The similarities between RA and cancer have led to the identification of commonly activated pathways with one being centered around uPAR.</p>
<p id="Par49">RA manifestation in joints is defined by persistent synovial inflammation, where leukocytes from the innate and adaptive immune system infiltrate the synovial compartment and interact with present synoviocytes [<xref ref-type="bibr" rid="CR116">116</xref>]. To support the influx, adhesion, and migration of cells into the synovial compartment, endothelial cells overexpress uPAR (Fig. <xref ref-type="fig" rid="Fig3">3a</xref>) [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. However, uPAR expression is limited to endothelial cells. Neutrophils stimulate the inflammatory process through secretion of uPA and domain 2-3 of uPAR, whereby the latter probably functions as a chemoattractant for other formyl peptide receptor expressing leukocytes (Fig. <xref ref-type="fig" rid="Fig3">3b</xref>) [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. The secreted uPA interacts in autocrine and paracrine fashion with uPAR on neutrophils, FLS, macrophages, and chondrocytes, enhancing the invasive and proliferative properties of these cells (Fig. <xref ref-type="fig" rid="Fig3">3c, d</xref>) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR120">120</xref>–<xref ref-type="bibr" rid="CR131">131</xref>]. The importance of uPAR has been confirmed by studies where knockdown of uPAR in FLS-inhibited proliferation, migration, and invasion in vitro [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, compared to their wildtype littermates, PLAUR−/− mice show significant reduction of arthritis incidence and severity in a collagen-induced arthritis model [<xref ref-type="bibr" rid="CR132">132</xref>]. However, an earlier study suggested that uPAR is not essential for RA development [<xref ref-type="bibr" rid="CR133">133</xref>]. Induction of arthritis by intra-articular uPA injection is not dependent on the uPAR-binding fragment of uPA. Furthermore, the arthritis incidence is similar in PLAUR−/− mice and their genetic counterparts after uPA injection [<xref ref-type="bibr" rid="CR133">133</xref>]. While this model results in joints with morphological features of arthritis, the question can be beckoned if intra-articular injection of uPA accurately reflects the etiology and progression of RA in humans.
<fig id="Fig3"><label>Fig. 3</label><caption><p>uPAR in rheumatoid arthritis. <bold>a</bold> uPAR on neo-angiogenic endothelium support the influx of inflammatory cells. <bold>b</bold> Neutrophils secrete uPA and uPAR-D2/3 further escalating the inflammation. <bold>c</bold> The uPA interacts via autocrine and paracrine methods with neutrophils, fibroblast-like synoviocytes, macrophages and chondrocytes, activating invasive, and proliferative pathways in these cells. <bold>d</bold> uPAR on osteoclasts promotes bone destruction. uPAR is represented by the red 3-domain structure as described in Fig. <xref ref-type="fig" rid="Fig1">1</xref> on the cell membrane of uPAR expressing cells and uPA by the green structure in the extracellular matrix and bound to uPAR</p></caption><graphic id="MO3" xlink:href="13550_2020_673_Fig3_HTML"></graphic></fig></p>
<p id="Par50">Besides influencing the inflammatory stage of RA, uPAR also attenuates the bone destruction occurring in late stage RA disease. Osteoclast differentiation, the subsequent bone destruction and bone mineral density (BMD), is significantly decreased in uPAR knockout mice and stimulated by uPAR overexpression [<xref ref-type="bibr" rid="CR134">134</xref>]. With this knowledge in mind, loss of BMD has been successfully inhibited in a lipopolysaccharide-induced bone destruction mouse model using the uPAR targeting peptide (Ȧ6) [<xref ref-type="bibr" rid="CR135">135</xref>].</p>
<p id="Par51">The therapeutic possibilities by targeting uPAR in vivo have been investigated using uPAR antisense treatment and adenovirus-mediated gene transfer of the amino terminal fragment of uPA fused to human serum albumin. Both inhibit cartilage invasion while the latter also decreases both the incidence and severity of the disease [<xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>]. However, blocking uPAR using the anti-uPAR monoclonal antibody mR1 in collagen-induced and delayed-type hypersensitivity arthritis models has no effect on RA progression [<xref ref-type="bibr" rid="CR118">118</xref>]. This discrepancy can partly be explained by difference in methods (antisense vs. adenovirus vs. monoclonal antibody administration), targeting uPA vs. uPAR, and by the differences in models used.</p>
<p id="Par52">While preclinical in vivo research is still inconclusive, several studies with clinically used agents have demonstrated that various treatment options for RA reach their effect by targeting the urokinase plasminogen activation pathway. Tenoxicam, a non-steroidal anti-inflammatory drug, has been shown to downregulate monocyte uPAR expression and hyaluronic acid treatment decreases the immunostaining for uPAR expression on FLS [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. Furthermore, the widely used corticosteroid deflazacort also modulates the urokinase pathway by inducing PAI-1 and inhibiting uPA and uPAR expression in RA FLS but not in healthy cells [<xref ref-type="bibr" rid="CR138">138</xref>]. Physiologically, proliferation and invasion of RA FLS are inhibited by deflazacort. In addition, soluble uPAR levels correlate with response to biologicals such as the tumor necrosis factor (TNF)-inhibitor adalimumab [<xref ref-type="bibr" rid="CR139">139</xref>].</p>
<p id="Par53">All-in-all there is substantial evidence for the role of uPA/uPAR/PAI-1 axis in RA development and progression. Although future studies will need to confirm this, targeting uPAR for imaging purposes has the potential of providing relevant information on disease activity, prognosis, and treatment effect [<xref ref-type="bibr" rid="CR140">140</xref>].</p>
</sec>
<sec id="Sec5">
<title>Central nervous system pathology: unraveling pathophysiology of degenerative disease</title>
<p id="Par54">The nervous system, with the brain as its helm, is the most complex and pivotal system of the human body. Therefore, neurodegenerative disorders, such as Alzheimer’s disease (AD) and Creutzfeld-Jakob disease (CJD), auto-immune diseases, such as multiple sclerosis (MS), and infectious diseases, such as cerebral malaria (CM) and acquired immunodeficiency syndrome dementia complex (ADC), have disastrous consequences for patients. The emergence of molecular imaging has enabled more in-depth research into these pathologies as well as possibilities for diagnosis and monitoring of disease before clinical features occur [<xref ref-type="bibr" rid="CR141">141</xref>–<xref ref-type="bibr" rid="CR144">144</xref>].</p>
<p id="Par55">While uPAR expression is very low, if not absent, in the adult brain, it plays a pivotal role in the developing brain (Fig. <xref ref-type="fig" rid="Fig4">4a</xref>) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. In the early brain binding of uPA to uPAR stimulated neuritogenesis, neuronal migration, and differentiation via both proteolytic and nonproteolytic pathways resulting in axonal growth and branching of both the central and peripheral nerves [<xref ref-type="bibr" rid="CR146">146</xref>–<xref ref-type="bibr" rid="CR150">150</xref>]. The uPA/uPAR axis is of such importance that dysregulation has been implicated with epilepsy, schizophrenia, and autism. <italic>PLAUR</italic>, the gene encoding uPAR, and its promotor have been found to be upregulated in autistic patients [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>]. Furthermore, in rats, uPAR expression was increased in interneurons after spontaneous seizures [<xref ref-type="bibr" rid="CR153">153</xref>]. On the other hand, uPAR−/− mice were more susceptible to seizures, increased anxiety, and altered social behavior; all characteristics of epilepsy, schizophrenia and autism [<xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR155">155</xref>]. The discovery that uPAR functions as a receptor for SRPX2, an important regulator of synapse formation, and that both are co-located both spatially and temporally in the developing brain, further implicates uPAR’s role in the (patho)physiology of the nervous system. Although the actual function of SRPX2 remains to be elucidated, the Y72S mutation in SRPX2 leads to an almost sixfold increased affinity for uPAR, and clinically manifests in seizures, speech deficit, and mental retardation [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR157">157</xref>].
<fig id="Fig4"><label>Fig. 4</label><caption><p>uPAR in degenerative nervous system disorders. <bold>a</bold> uPAR expression is practically absent in the healthy human brain. In Alzheimer’s disease uPAR expression is found on (<bold>b</bold>) cortical neurons, (<bold>c</bold>) activated microglial cells after exposure to the amyloid plaques, and (<bold>d</bold>) in the vascular wall promoting uPA activation, subsequent extracellular matrix breakdown and corresponding spontaneous hemorrhages. In multiple sclerosis, uPAR (<bold>e</bold>) is expressed on inflammatory cells and activated microglial cells promoting local damage. <bold>f</bold> Furthermore, uPAR expression on dendritic cells influences subsequent T cell differentiation. uPAR is represented by the red 3-domain structure as described in Fig. <xref ref-type="fig" rid="Fig1">1</xref> on the cell membrane of uPAR expressing cells and uPA by the green structure in the extracellular matrix and bound to uPAR</p></caption><graphic id="MO4" xlink:href="13550_2020_673_Fig4_HTML"></graphic></fig></p>
<p id="Par56">Various neurodegenerative diseases present with enhanced uPAR expression. AD is the leading cause of dementia and can be characterized pathologically as intracellular tangles and extracellular deposition of amyloid β creating senile plaques [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. uPAR expression has been found in both the cortical neurons and the vascular wall of AD patients (Fig. <xref ref-type="fig" rid="Fig4">4b</xref>) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR160">160</xref>–<xref ref-type="bibr" rid="CR162">162</xref>]. Interestingly, the cerebellum, a region of the brain that is usually not affected by AD, is negative for uPAR in these patients [<xref ref-type="bibr" rid="CR162">162</xref>]. Corresponding in vitro studies demonstrates that microglia upregulate uPAR mRNA and protein after exposure to aggregated amyloid β (Fig. <xref ref-type="fig" rid="Fig4">4c</xref>) [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR162">162</xref>]. Furthermore, uPA and plasminogen activity is increased, which could lead to the vulnerability of the cerebral vessel wall due to extracellular matrix breakdown and corresponding spontaneous hemorrhages observed in AD (Fig. <xref ref-type="fig" rid="Fig4">4d</xref>) [<xref ref-type="bibr" rid="CR161">161</xref>]. In CJD, another fatal degenerative disease with a mean survival of 7.3+/−0.2 months after clinical onset, significantly more neurons, primarily focused in cortical layer 3-5, express uPAR, where the expression has been associated with damaged neurons as seen by chromatin condensation, hypertrophic swelling, and degeneration [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]. Microglial cells, but not astrocytes, also express uPAR [<xref ref-type="bibr" rid="CR160">160</xref>].</p>
<p id="Par57">MS is an autoimmune disease where an immune response is mounted against the central nervous system by autoreactive lymphocytes resulting in lesions that are characterized by inflammation, demyelination, and degeneration of neurons [<xref ref-type="bibr" rid="CR164">164</xref>]. While autopsy material from healthy brains exhibits almost no uPAR expression, uPAR gene and protein expression are significantly elevated on MS microvessels, mononuclear cells, macrophages, pericytes, and smooth muscle cells [<xref ref-type="bibr" rid="CR165">165</xref>–<xref ref-type="bibr" rid="CR169">169</xref>]. Microglial cells cultured from an MS patient show an activated morphology in combination with high levels of uPAR, whereas control microglial cells from normal brain tissue express little to no uPAR mRNA and protein. After in vitro activation, these normal microglia present a spindle-shape morphology and express uPAR [<xref ref-type="bibr" rid="CR170">170</xref>]. In an animal model of experimental autoimmune encephalomyelitis (EAE), elevated uPAR expression is detected in the inflammatory lesions by both immune and microglial cells (Fig. <xref ref-type="fig" rid="Fig4">4e</xref>) and increased uPA activity at the dorsal horn and central spinal cord [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>]. EAE in uPAR−/− mice is characterized by a delayed onset, chronicity, persisting inflammatory cuffs with increased levels of uPA and more extensive demyelination. The dysregulated adhesion and migration of inflammatory cells in uPAR−/− mice explains the delayed onset while the inability to recycle uPA via uPAR reflects the increased neuronal damage [<xref ref-type="bibr" rid="CR173">173</xref>]. In a later study, uPAR−/− mice with EAE are shown to exhibit more severe disease with a twofold increase in microglial activation and increased infiltration of mononuclear cells but reduced immune response, rendering the mouse incapable of recovery [<xref ref-type="bibr" rid="CR174">174</xref>]. The recently revealed crosstalk between the coagulation pathway (coagulation factor XII, FXII) and immunity in MS underlines the role of uPAR in this disease. uPAR on dendritic cells (Fig. <xref ref-type="fig" rid="Fig4">4f</xref>) is responsible for the immune modulatory function of FXII, tipping the balance of T cell differentiation toward the TH17 phenotype, as a signal receiver and relaying the message, via CD11b integrin, intracellularly (Fig. <xref ref-type="fig" rid="Fig4">4f</xref>) [<xref ref-type="bibr" rid="CR175">175</xref>]. All-in-all, there is initial evidence that uPAR plays a fundamental role in MS, but whether uPAR expression is protective or destructive remains to be elucidated and, considering uPAR’s multifaceted aspects, could actually be both.</p>
<p id="Par58">Various infectious diseases can have drastic neurological manifestations. ADC is one of the most severe consequences of human immunodeficiency virus 1 (HIV-1) infection [<xref ref-type="bibr" rid="CR176">176</xref>]. The lesions showed membranous uPAR expression in immunohistochemical stainings that colocalized with HIV-1 p24 antigen in both macrophages, microglial, and multinucleated giant cells [<xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR178">178</xref>]. Not coincidentally, soluble uPAR levels are a strong independent predictor for HIV-1 infection survival [<xref ref-type="bibr" rid="CR179">179</xref>]. While combination antiretroviral therapy has successfully dropped the incidence of ADC from 20 to 5%, milder forms of HIV-associated neurocognitive disorder still occur with an incidence of 20-50% [<xref ref-type="bibr" rid="CR176">176</xref>]. No study has evaluated uPAR in these cases. Plasmodium falciparum is another infectious agent that can lead to severe neurologic impairment with persistent neurocognitive deficits characterized as CM [<xref ref-type="bibr" rid="CR180">180</xref>]. In post-mortem specimens of patients with CM uPAR expression, detected by immunohistochemical staining, of microglia, reactive astrocytes and endothelial cells is limited to areas with microvasculature containing parasitized erythrocytes, petechial bleedings and Dürck’s granulomas [<xref ref-type="bibr" rid="CR181">181</xref>]. In the mouse model of CM, known as severe malaria (SM) as the syndrome in mice is not limited to the brain, uPAR deficiency has profound effect on thrombocytopenia. Platelet trapping, which is a reliable predictor of forthcoming death, does not occur in uPAR−/− mice [<xref ref-type="bibr" rid="CR182">182</xref>]. The current theory holds that platelets form an adhesive surface in microvascular beds for parasitized erythrocytes in the cerebrum and consequently play a pivotal role in the development of CM [<xref ref-type="bibr" rid="CR183">183</xref>].</p>
<p id="Par59">While in most neurological disease processes, there is no clear indication whether uPAR expression is protective or destructive, the evidence currently accumulated suggests a critical role for uPAR in the pathophysiology of AD, MS, ADC, and MC. Grossly, aberrant uPAR expression is linked to an altered immune-phenotype, consequently altering the progressing of the disease. In addition to the post-mortem pathology and animal models, we are dependent on for research, an uPAR targeting tracer may enable in vivo imaging of the various pathophysiological processes going on in real-time and consequently enrich our understanding of these disease. This knowledge can potentially be used to dictate treatment and monitor disease based on uPAR signaling.</p>
</sec>
<sec id="Sec6">
<title>Inflammatory bowel disease: imaging macrophage polarization</title>
<p id="Par60">Inflammatory bowel disease (IBD) is an umbrella term consisting of chronic relapsing inflammatory disorders of the intestinal tract. Ulcerative colitis (UC) characterizes itself as inflammation of the mucosal layer of the colon while Crohn’s disease (CD) displays transmural inflammation of any part of the gastrointestinal tract ranging from the mouth to the anus [<xref ref-type="bibr" rid="CR184">184</xref>]. The current gold standard for diagnosis and surveillance of IBD is endoscopy and X-ray exams, but these techniques are limited by their invasiveness and patient tolerance. Molecular imaging might provide an opportunity for accurate non-invasive or endoscopic specification of IBD presence, transmural and extra-intestinal tissue involvement, and specific inflammatory profile [<xref ref-type="bibr" rid="CR185">185</xref>–<xref ref-type="bibr" rid="CR188">188</xref>]. While the etiology of IBD has not been fully elucidated yet, genetic, environmental, and immune factors have all been implicated.</p>
<p id="Par61">The impaired immune response leads to extensive tissue remodeling and degradation in which the plasminogen activation cascade, including various MMPs and localized by uPAR, plays a major role [<xref ref-type="bibr" rid="CR189">189</xref>–<xref ref-type="bibr" rid="CR192">192</xref>]. Patients with active IBD have increased uPAR specific for macrophages at active lesions. Interestingly, uPAR D1-D3 is downregulated while uPAR D2-D3 is increased. In two different IBD mice models, uPAR expression has shown specific for CX<sub>3</sub>CR<sub>1</sub><sup>+</sup> macrophages and mirrored disease onset [<xref ref-type="bibr" rid="CR193">193</xref>]. This subset of macrophages has an anti-inflammatory phenotype [<xref ref-type="bibr" rid="CR194">194</xref>]. Therefore, knocking out uPAR exaggerates disease by amplifying the release of pro-inflammatory cytokines and altering polarization of macrophages. Low expression of uPAR D1-D3 and high expression of uPAR D2-3 by IBD patients can consequently lead to increased inflammation and disrupted bacterial removal (Fig. <xref ref-type="fig" rid="Fig5">5a, b</xref>) [<xref ref-type="bibr" rid="CR193">193</xref>]. The therapeutic potential that targeting macrophages, and in extension uPAR, brings has not been unnoticed [<xref ref-type="bibr" rid="CR195">195</xref>]. A cyclic peptide based of amino acids 88-92 of uPAR, [SRSRY], competed with uPAR for binding to FPRL1 but exerted an opposite effect: inhibiting migration as opposed to promoting it [<xref ref-type="bibr" rid="CR196">196</xref>]. In vivo, [SRSRY], altered macrophage polarization and migration in colitis mice models and as such attenuated disease severity [<xref ref-type="bibr" rid="CR197">197</xref>]. By competing with the migration sensitive epitope that becomes available after uPAR cleavage, [SRSRY], diminishes the destructive potential of uPAR D2-D3. While the research is still in its infancy, there is potential to determine macrophage polarization and disease progression by molecular imaging of uPAR. Determining the right epitope to direct the uPAR targeting moiety to, will be crucial for correct implementation and interpretation of uPAR-targeted molecular imaging in IBD as well as for other applications (Table <xref ref-type="table" rid="Tab1">1</xref>). If addressed well, uPAR imaging has the potential to non-invasively diagnose IBD by identifying aberrant macrophage polarization and subsequently be used to monitor disease activity.
<fig id="Fig5"><label>Fig. 5</label><caption><p>uPAR in inflammatory bowel disease. <bold>a</bold> Macrophage uPAR D1-D3 expression plays a significant role in the bacterial removal while (<bold>b</bold>) in inflammatory bowel disease macrophage differentiation is altered with as consequence an increase in uPAR D2-D3 expression and inadequate microbial maintenance. uPAR is represented by the red 3-domain structure as described in Fig. <xref ref-type="fig" rid="Fig1">1</xref> on the cell membrane of uPAR expressing cells</p></caption><graphic id="MO5" xlink:href="13550_2020_673_Fig5_HTML"></graphic></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>uPAR targeting imaging agents</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Agent</th><th>Classification</th><th>Targeting epitope</th><th>Imaging modality</th><th>Imaging window</th><th>Notes</th><th>Translation stage</th><th>Ref</th></tr></thead><tbody><tr><td>Cy5.5-mATF-IO</td><td>ATF-based NP</td><td>uPA-binding region</td><td>MRI, optical</td><td>24-48 h</td><td>Mouse ATF</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR198">198</xref>, <xref ref-type="bibr" rid="CR199">199</xref>]</td></tr><tr><td>hATF-Cy5.5-IO-Nos</td><td>ATF-based NP</td><td>uPA-binding region</td><td>MRI, optical</td><td>n.v.t.</td><td>Human ATF</td><td>In vitro preclinical</td><td>[<xref ref-type="bibr" rid="CR200">200</xref>]</td></tr><tr><td>ATF-I<sup>125</sup></td><td>ATF-based</td><td>uPA-binding region</td><td>n.a.</td><td>n.v.t.</td><td></td><td>In vitro preclinical</td><td>[<xref ref-type="bibr" rid="CR201">201</xref>]</td></tr><tr><td>NIR-830-mATF-IONP</td><td>ATF-based NP</td><td>uPA-binding region</td><td>PA, optical</td><td>24 h</td><td>Mouse ATF</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR202">202</xref>]</td></tr><tr><td>ATF-IONP-Gem</td><td>ATF-based NP</td><td>uPA-binding region</td><td>MRI</td><td>48 h</td><td>Mouse and human ATF</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR203">203</xref>]</td></tr><tr><td>NIR-830-hATF-IONP</td><td>ATF-based NP</td><td>uPA-binding region</td><td>Optical</td><td>24 h</td><td>Human ATF</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR204">204</xref>]</td></tr><tr><td>NAc-dD-CHA-F-dS-dR-Y-L-W-S-βAla)<sub>2</sub>-K-K(DOTA)-NH<sub>2</sub>-<sup>111</sup>In</td><td>Peptide</td><td>uPA-binding region</td><td>n.a.</td><td>n.v.t.</td><td></td><td>In vitro preclinical</td><td>[<xref ref-type="bibr" rid="CR201">201</xref>]</td></tr><tr><td><sup>99m</sup>Tc-Hynic-PEG-AE105</td><td>Peptide</td><td>uPA-binding region</td><td>SPECT</td><td>4-6 h</td><td></td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR205">205</xref>]</td></tr><tr><td><sup>64</sup>Cu-DOTA-AE105</td><td>Peptide</td><td>uPA-binding region</td><td>PET</td><td>24 h</td><td></td><td>Phase I clinical</td><td>[<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR219">219</xref>–<xref ref-type="bibr" rid="CR222">222</xref>, <xref ref-type="bibr" rid="CR224">224</xref>]</td></tr><tr><td><sup>68</sup>Ga-NOTA-AE105</td><td>Peptide</td><td>uPA-binding region</td><td>PET</td><td>10 min-1 h</td><td></td><td>Phase I clinical</td><td>[<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR206">206</xref>]</td></tr><tr><td>ICG-Glu-Glu-AE105</td><td>Peptide</td><td>uPA-binding region</td><td>Optical</td><td>6-24 h</td><td></td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR207">207</xref>–<xref ref-type="bibr" rid="CR209">209</xref>]</td></tr><tr><td>CH1055-4Glu-AE105</td><td>Peptide</td><td>uPA-binding region</td><td>Optical</td><td>72-96 h</td><td></td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR210">210</xref>]</td></tr><tr><td>AF680-2G10</td><td>Antibody</td><td>uPA-binding region</td><td>Optical</td><td>48-96 h</td><td>Recombinant antibody with trastuzumab Fc region</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR211">211</xref>, <xref ref-type="bibr" rid="CR212">212</xref>]</td></tr><tr><td><sup>111</sup>ln-2G10</td><td>Antibody</td><td>uPA-binding region</td><td>SPECT</td><td>48-120 h</td><td>Recombinant antibody with trastuzumab Fc region</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR211">211</xref>, <xref ref-type="bibr" rid="CR212">212</xref>]</td></tr><tr><td>AF680-3C6</td><td>Antibody</td><td>β1-binding region</td><td>Optical</td><td>48-96 h</td><td>Recombinant antibody with trastuzumab Fc region</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR211">211</xref>]</td></tr><tr><td><sup>111</sup>ln-3C6</td><td>Antibody</td><td>β1-binding region</td><td>SPECT</td><td>48-96 h</td><td>Recombinant antibody with trastuzumab Fc region</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR211">211</xref>]</td></tr><tr><td><sup>111</sup>In-ZW800-1-ATN-658 (Hybrid ATN-658)</td><td>Antibody</td><td>Domain 3, amino acids 268-275</td><td>Optical, SPECT</td><td>24-72 h</td><td>Mouse antibody</td><td>In vivo preclinical</td><td>[<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR214">214</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>NP</italic> nanoparticle, <italic>MRI</italic> magnetic resonance imaging, <italic>PET</italic> positron emission tomography, <italic>SPECT</italic> single photon-emission computed tomography, <italic>h</italic> hours, <italic>min</italic> minute, <italic>n.a.</italic> not applicable, <italic>ATF</italic> amino-terminal fragment</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec7">
<title>uPAR imaging</title>
<p id="Par62">uPAR has been targeted for molecular imaging according by various approaches, each with its own advantages and disadvantages (Table <xref ref-type="table" rid="Tab1">1</xref>, Fig. <xref ref-type="fig" rid="Fig6">6a</xref>). The first peptides targeting uPAR were ligand-based, utilizing the growth-factor domain of urokinase [<xref ref-type="bibr" rid="CR215">215</xref>]. Targeting this natural interaction between uPA and uPAR with ATF or ATF-like constructs has been employed for magnetic-resonance imaging, near-infrared imaging, photo-acoustic imaging, and nuclear-imaging [<xref ref-type="bibr" rid="CR198">198</xref>–<xref ref-type="bibr" rid="CR204">204</xref>]. With a molecular weight of 18.5 kilodalton, ATF is cleared rapidly by the kidneys resulting in quick imaging times (30 min to 2 h) but also minimizing the time available to get sufficient contrast [<xref ref-type="bibr" rid="CR216">216</xref>]. Conjugating ATF to nanoparticles (NPs) enhances blood circulation times resulting in optimal imaging times around 24-48 h after injection in vivo [<xref ref-type="bibr" rid="CR198">198</xref>, <xref ref-type="bibr" rid="CR199">199</xref>, <xref ref-type="bibr" rid="CR202">202</xref>, <xref ref-type="bibr" rid="CR204">204</xref>]. Another advantage of ATF-NPs is their internalization, potentially increasing contrast [<xref ref-type="bibr" rid="CR199">199</xref>, <xref ref-type="bibr" rid="CR200">200</xref>, <xref ref-type="bibr" rid="CR204">204</xref>]. Nonetheless, whether conjugated to a NP or not, uPAR targeting efficiency with ATF is dependent on the absence of endogenous urokinase on the majority of uPAR copies present and markedly reduced in models with high uPA expression [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR201">201</xref>].
<fig id="Fig6"><label>Fig. 6</label><caption><p>Targeting uPAR for molecular imaging. <bold>a</bold> Representation of binding domains of the uPAR imaging agents currently under development, their classification and suitable imaging modality. <bold>b</bold> Positive primary lesion with uPAR PET in human prostate cancer after injection of 64Cu-DOTA-AE105. Images adapted from Skovgaard et al. [218] and used under the terms of the Creative Commons CC BY license. <bold>c</bold> NIR optical imaging of orthotopic colon cancer with hybrid ATN-658</p></caption><graphic id="MO6" xlink:href="13550_2020_673_Fig6_HTML"></graphic></fig></p>
<p id="Par63">An alternative uses a 9-mer peptide which has led to the first uPAR PET clinical trials. This peptide, AE105, is the refined version of a 15-mer peptide identified by a phage display with uPAR-transfected cell lines and binds uPAR at the uPA-binding site in a species specific manner, like ATF [<xref ref-type="bibr" rid="CR217">217</xref>, <xref ref-type="bibr" rid="CR218">218</xref>]. While AE105 has also been conjugated with (radio)-labels for single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) in preclinical oncology studies, this section will focus on positron-emission tomography as AE105 PET is further along the clinical pipeline [<xref ref-type="bibr" rid="CR205">205</xref>–<xref ref-type="bibr" rid="CR210">210</xref>, <xref ref-type="bibr" rid="CR219">219</xref>, <xref ref-type="bibr" rid="CR220">220</xref>]. Initially, AE105 has been conjugated with the metal chelator DOTA and subsequently labeled with <sup>64</sup>Cu. <sup>64</sup>Cu-DOTA-AE105 specifically targets uPAR positive lesions in preclinical studies with signal corresponding to uPAR expression levels and epitope availability, but also resulted in high non-specific liver-uptake [<xref ref-type="bibr" rid="CR221">221</xref>, <xref ref-type="bibr" rid="CR222">222</xref>]. Alternative <sup>64</sup>Cu, <sup>68</sup>Ga, and <sup>18</sup>F tracer-chelator combinations decrease non-specific uptake but at the cost of lower tumor specific signal [<xref ref-type="bibr" rid="CR223">223</xref>]. Phase I clinical trials with <sup>64</sup>Cu-DOTA-AE105 have shown no adverse events or detectable pharmacological effects related to the tracer. Furthermore, all primary tumors (bladder, breast, and prostate) and the majority of metastasis are identifiable between 1 and 24 h after administration (Fig. <xref ref-type="fig" rid="Fig6">6b</xref>). In this study, two liver metastasis have not been visualized due to high background signal [<xref ref-type="bibr" rid="CR13">13</xref>]. In addition, the feasibility of measuring mean <sup>64</sup>Cu-DOTA-AE105 uptake in the arterial beds of these patients in order to non-invasively identify atherogenic lesions has been retrospectively evaluated [<xref ref-type="bibr" rid="CR224">224</xref>]. While activated macrophages have higher uPAR expression, clear imaging capability of atherosclerosis has yet to be demonstrated with this tracer. The possibility to scan at early time points and the independence of <sup>68</sup>Ga on an on-site cyclotron prompted to phase I trials of <sup>68</sup>Ga-NOTA-AE105 [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR223">223</xref>]. <sup>68</sup>Ga-Nota-AE105 resulted in decreased liver signal and specifically identified both primary tumors and one metastasis missed in the standard work up [<xref ref-type="bibr" rid="CR14">14</xref>]. While initial clinical trial results are promising, allowing for rapid identification of cancerous lesions, endogenous uPA expression could present the biggest limiting factor of AE105 molecular imaging, especially in diseases where the expression of uPA is likely to be increased and paramount for outcomes [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR225">225</xref>].</p>
<p id="Par64">Another approach utilizes monoclonal antibodies to target uPAR. Both antibodies 2G10 and 3C6 are identified from a human fragment of the antigen binding (Fab) phage display library to have high affinities for uPAR. Consequently, these are expressed as recombinant IgG’s using the trastuzumab Fc domain [<xref ref-type="bibr" rid="CR226">226</xref>]. 2G10 competes with uPA for uPAR binding while 3C6 prevents β1 integrin association with uPAR [<xref ref-type="bibr" rid="CR211">211</xref>]. In human xenograft breast cancer models, 2G10 shows higher tumor uptake with NIRF and SPECT/CT than 3C6, probably due to higher epitope availability for 2G10 [<xref ref-type="bibr" rid="CR212">212</xref>, <xref ref-type="bibr" rid="CR226">226</xref>]. Another thoroughly and extensively studied anti-uPAR antibody is ATN658. ATN658 was raised against a soluble D2-D3 uPAR fragment and recognizes domain 3 of uPAR, close to the C-terminus at amino acids 268-275 [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR227">227</xref>]. ATN658 enables and anti-tumor effect by impairing α5β1 integrin adhesion to the ECM and is not effected by uPA or vitronectin interaction with uPAR [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR228">228</xref>, <xref ref-type="bibr" rid="CR229">229</xref>]. In colorectal and oral xenograft cancer models NIRF and SPECT hybrid-labeled ATN658, accurately localized lesions as small as 1-2 mm in size in a range from 24 to 72 h post-injection (Fig. <xref ref-type="fig" rid="Fig6">6c</xref>) [<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR214">214</xref>]. ATN658 has been humanized and is awaiting clinical translation for NIRF-imaging [<xref ref-type="bibr" rid="CR229">229</xref>].</p>
<p id="Par65">A thorough assessment of the uPAR targeting agents reveals crucial differences in modalities, biodistributions, imaging windows, epitopes targeted, and production methods. Therefore, a one-size-fits-all solution to target all types of diseases where uPAR is involved is probably not feasible, like for most, if not all, molecular targets [<xref ref-type="bibr" rid="CR5">5</xref>]. For instance, peptides may find their utility in more acute situations such as atherosclerosis imaging. Antibodies seem more ideal for abdominal imaging where the high non-specific background of kidneys can be a hindrance or in more elective settings where a large imaging window is desired. Not only will selecting an optimal agent be challenging, also designing and selecting preclinical animal models that take the species specificity of the imaging agents into account, since most tracers designed for clinical applications have high affinities for human uPAR but no or reduced affinities for mouse uPAR [<xref ref-type="bibr" rid="CR201">201</xref>, <xref ref-type="bibr" rid="CR218">218</xref>, <xref ref-type="bibr" rid="CR226">226</xref>, <xref ref-type="bibr" rid="CR227">227</xref>].</p>
</sec>
</sec>
<sec id="Sec8">
<title>Conclusions</title>
<p id="Par66">uPAR is a central unit in regulating ECM proteolysis, migration, differentiation, and proliferation and hereby implicated in a range of inflammatory-related diseases, often holding pivotal roles and tipping the balance toward disease aggravation. Even though uPAR is almost completely absent in normal tissue, it will likely not be an appropriate target for the diagnosis of diseases, due to the common pathophysiological role. However, when it comes to visualization of diagnosed disease lesions, whether it be plaques that are about to rupture or aggravation of RA or IBD, uPAR plays a central pathophysiological role prompting its usefulness as a molecular imaging target. Furthermore, molecular imaging of uPAR can unravel the complex pathophysiological processes occurring, increasing our understanding of the disease, and consequently allowing the development of novel therapies, ultimately improving patient outcomes.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AD</term>
<def>
<p id="Par2">Alzheimer’s disease</p>
</def>
</def-item>
<def-item>
<term>ADC</term>
<def>
<p id="Par3">Acquired immunodeficiency syndrome dementia complex</p>
</def>
</def-item>
<def-item>
<term>ATF</term>
<def>
<p id="Par4">Amino-terminal fragment of urokinase</p>
</def>
</def-item>
<def-item>
<term>BMD</term>
<def>
<p id="Par5">Bone mineral density</p>
</def>
</def-item>
<def-item>
<term>BPTI</term>
<def>
<p id="Par6">Bovine pancreas trypsin inhibitor</p>
</def>
</def-item>
<def-item>
<term>CD</term>
<def>
<p id="Par7">Crohn’s disease</p>
</def>
</def-item>
<def-item>
<term>CJD</term>
<def>
<p id="Par8">Creutzfeld-Jakob disease</p>
</def>
</def-item>
<def-item>
<term>CM</term>
<def>
<p id="Par9">Cerebral malaria</p>
</def>
</def-item>
<def-item>
<term>D</term>
<def>
<p id="Par10">Domain: D1, D2, D3, D1-3, D1-2, D2-3</p>
</def>
</def-item>
<def-item>
<term>ECM</term>
<def>
<p id="Par11">Extracellular matrix</p>
</def>
</def-item>
<def-item>
<term>FLS</term>
<def>
<p id="Par12">Fibroblast-like synoviocytes</p>
</def>
</def-item>
<def-item>
<term>FPRL1</term>
<def>
<p id="Par13">Formyl peptide receptor-like 1</p>
</def>
</def-item>
<def-item>
<term>GPI</term>
<def>
<p id="Par14">Glycosylphosphatidylinositol</p>
</def>
</def-item>
<def-item>
<term>GPCR</term>
<def>
<p id="Par15">G protein-coupled receptors</p>
</def>
</def-item>
<def-item>
<term>HIV-1</term>
<def>
<p id="Par16">Human immunodeficiency virus 1</p>
</def>
</def-item>
<def-item>
<term>IBD</term>
<def>
<p id="Par17">Inflammatory bowel disease</p>
</def>
</def-item>
<def-item>
<term>LRP1</term>
<def>
<p id="Par18">Lipoprotein receptor-related protein 1</p>
</def>
</def-item>
<def-item>
<term>MMP</term>
<def>
<p id="Par19">Matrix metalloprotease</p>
</def>
</def-item>
<def-item>
<term>MS</term>
<def>
<p id="Par20">Multiple sclerosis</p>
</def>
</def-item>
<def-item>
<term>NIRF</term>
<def>
<p id="Par21">Near-infrared fluorescence</p>
</def>
</def-item>
<def-item>
<term>NP</term>
<def>
<p id="Par22">Nanoparticle</p>
</def>
</def-item>
<def-item>
<term>PAI-1</term>
<def>
<p id="Par23">Plasminogen activator inhibitor type 1</p>
</def>
</def-item>
<def-item>
<term>PET</term>
<def>
<p id="Par24">Positron emission tomography</p>
</def>
</def-item>
<def-item>
<term>RA</term>
<def>
<p id="Par25">Rheumatoid arthritis</p>
</def>
</def-item>
<def-item>
<term>SM</term>
<def>
<p id="Par26">Severe malaria</p>
</def>
</def-item>
<def-item>
<term>SPECT</term>
<def>
<p id="Par27">Single-photon emission computed tomography</p>
</def>
</def-item>
<def-item>
<term>TIMP1</term>
<def>
<p id="Par28">Tissue inhibitor of matrix metalloproteinases 1</p>
</def>
</def-item>
<def-item>
<term>TNF</term>
<def>
<p id="Par29">Tumor necrosis factor</p>
</def>
</def-item>
<def-item>
<term>UC</term>
<def>
<p id="Par30">Ulcerative colitis</p>
</def>
</def-item>
<def-item>
<term>uPA</term>
<def>
<p id="Par31">Urokinase plasminogen activator</p>
</def>
</def-item>
<def-item>
<term>uPAR</term>
<def>
<p id="Par32">Urokinase plasminogen activator receptor</p>
</def>
</def-item>
<def-item>
<term>VSMC</term>
<def>
<p id="Par33">Vascular smooth muscle cell</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Code availability</title>
<p>Not applicable.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>VB designed the manuscript, performed the literature search and data analysis, and drafted the first version. RH made the figures and critically revised the manuscript. LFdGO, PQ, PK, and AV critically revised the manuscript. CS designed and critically revised the manuscript. The author(s) read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>CS was in part funded by the European Commission under two Marie Skłodowska-Curie Action awards: H2020-MSCA-RISE-2019 (Project number: 872860 - PRISAR2) and H2020-MSCA-ITN-2019 (Project number: 857894 - CAST).</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>Not applicable.</p>
</notes>
<notes id="FPar1">
<title>Ethics approval and consent to participate</title>
<p id="Par67">This review does not contain any studies with human participants or animals performed by any of the authors.</p>
</notes>
<notes id="FPar2">
<title>Consent for publication</title>
<p id="Par68">Not applicable.</p>
</notes>
<notes id="FPar3" notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par69">Authors VB, RH, LFdGO, PQ, PK, AV, and CS declare that they have no conflict of interest.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonnans</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Werb</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Remodelling the extracellular matrix in development and disease</article-title>
<source/>Nat Rev Mol Cell Biol
          <year>2014</year>
<volume>15</volume>
<fpage>786</fpage>
<lpage>801</lpage>
<pub-id pub-id-type="doi">10.1038/nrm3904</pub-id>
<pub-id pub-id-type="pmid">25415508</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamburg</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>FS</given-names>
</name>
</person-group>
<article-title>The path to personalized medicine</article-title>
<source/>N Engl J Med
          <year>2010</year>
<volume>363</volume>
<fpage>301</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMp1006304</pub-id>
<pub-id pub-id-type="pmid">20551152</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KH</given-names>
</name>
</person-group>
<article-title>Molecular imaging in the era of personalized medicine</article-title>
<source/>J Pathol Trans Med
          <year>2015</year>
<volume>49</volume>
<fpage>5</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.4132/jptm.2014.10.24</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herschman</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>Molecular imaging: looking at problems, seeing solutions</article-title>
<source/>Science (New York, NY)
          <year>2003</year>
<volume>302</volume>
<fpage>605</fpage>
<lpage>608</lpage>
<pub-id pub-id-type="doi">10.1126/science.1090585</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baart</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Boonstra</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Sier</surname>
<given-names>CFM</given-names>
</name>
</person-group>
<article-title>uPAR directed-imaging of head-and-neck cancer</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>20519</fpage>
<lpage>20520</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.16240</pub-id>
<pub-id pub-id-type="pmid">28423554</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>C</given-names>
</name>
<collab>Dent OF</collab>
<name>
<surname>Mohamedali</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kwun</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0117786</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0117786</pub-id>
<pub-id pub-id-type="pmid">25692297</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willmann</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>van Bruggen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dinkelborg</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Gambhir</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Molecular imaging in drug development</article-title>
<source/>Nat Rev Drug Discov
          <year>2008</year>
<volume>7</volume>
<fpage>591</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1038/nrd2290</pub-id>
<pub-id pub-id-type="pmid">18591980</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Design and development of molecular imaging probes</article-title>
<source/>Curr Top Med Chem
          <year>2010</year>
<volume>10</volume>
<fpage>1227</fpage>
<lpage>1236</lpage>
<pub-id pub-id-type="doi">10.2174/156802610791384225</pub-id>
<pub-id pub-id-type="pmid">20388106</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boonstra</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>de Geus</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Prevoo</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Hawinkels</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>van de Velde</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Kuppen</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Selecting targets for tumor imaging: an overview of cancer-associated membrane proteins</article-title>
<source/>Biomarkers in cancer
          <year>2016</year>
<volume>8</volume>
<fpage>119</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.4137/bic.S38542</pub-id>
<pub-id pub-id-type="pmid">27721658</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Regulation of cell signalling by uPAR</article-title>
<source/>Nat Rev Mol Cell Biol
          <year>2010</year>
<volume>11</volume>
<fpage>23</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2821</pub-id>
<pub-id pub-id-type="pmid">20027185</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boonstra</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Verspaget</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Ganesh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kubben</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Vahrmeijer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>van de Velde</surname>
<given-names>CJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical applications of the urokinase receptor (uPAR) for cancer patients</article-title>
<source/>Curr Pharm Des
          <year>2011</year>
<volume>17</volume>
<fpage>1890</fpage>
<lpage>1910</lpage>
<pub-id pub-id-type="doi">10.2174/138161211796718233</pub-id>
<pub-id pub-id-type="pmid">21711239</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahmood</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mihalcioiu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rabbani</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications</article-title>
<source/>Front Oncol
          <year>2018</year>
<volume>8</volume>
<fpage>24</fpage>
<pub-id pub-id-type="doi">10.3389/fonc.2018.00024</pub-id>
<pub-id pub-id-type="pmid">29484286</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Skovgaard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brandt-Larsen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>CH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>First-in-human uPAR PET: imaging of cancer aggressiveness</article-title>
<source/>Theranostics.
          <year>2015</year>
<volume>5</volume>
<fpage>1303</fpage>
<lpage>1316</lpage>
<pub-id pub-id-type="doi">10.7150/thno.12956</pub-id>
<pub-id pub-id-type="pmid">26516369</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skovgaard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brandt-Larsen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klausen</surname>
<given-names>TL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety, dosimetry, and tumor detection ability of (68)Ga-NOTA-AE105: first-in-human study of a novel radioligand for uPAR PET imaging</article-title>
<source/>J Nucl Med
          <year>2017</year>
<volume>58</volume>
<fpage>379</fpage>
<lpage>386</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.116.178970</pub-id>
<pub-id pub-id-type="pmid">27609788</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruneau</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Szepetowski</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The role of the urokinase receptor in epilepsy, in disorders of language, cognition, communication and behavior, and in the central nervous system</article-title>
<source/>Curr Pharm Des
          <year>2011</year>
<volume>17</volume>
<fpage>1914</fpage>
<lpage>1923</lpage>
<pub-id pub-id-type="doi">10.2174/138161211796718198</pub-id>
<pub-id pub-id-type="pmid">21711233</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>YF</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis</article-title>
<source/>Cell Mol Immunol
          <year>2018</year>
<volume>15</volume>
<fpage>171</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1038/cmi.2016.60</pub-id>
<pub-id pub-id-type="pmid">28090093</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoppelli</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Corti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Soffientini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cassani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Assoian</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1985</year>
<volume>82</volume>
<fpage>4939</fpage>
<lpage>4943</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.82.15.4939</pub-id>
<pub-id pub-id-type="pmid">2991901</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vassalli</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Baccino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Belin</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase</article-title>
<source/>J Cell Biol
          <year>1985</year>
<volume>100</volume>
<fpage>86</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.100.1.86</pub-id>
<pub-id pub-id-type="pmid">3880760</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asahina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yoshiyama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer’s disease brain</article-title>
<source/>Clin Neuropathol
          <year>2001</year>
<volume>20</volume>
<fpage>60</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">11327298</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ploug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins</article-title>
<source/>FEBS Lett
          <year>1994</year>
<volume>349</volume>
<fpage>163</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1016/0014-5793(94)00674-1</pub-id>
<pub-id pub-id-type="pmid">8050560</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huai</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Mazar</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Callahan</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<source/>Science (New York, NY)
          <year>2006</year>
<volume>311</volume>
<fpage>656</fpage>
<lpage>659</lpage>
<pub-id pub-id-type="doi">10.1126/science.1121143</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eden</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Archinti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Furlan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Degryse</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The urokinase receptor interactome</article-title>
<source/>Curr Pharm Des
          <year>2011</year>
<volume>17</volume>
<fpage>1874</fpage>
<lpage>1889</lpage>
<pub-id pub-id-type="doi">10.2174/138161211796718215</pub-id>
<pub-id pub-id-type="pmid">21711237</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huai</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mazar</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Callahan</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes</article-title>
<source/>Nat Struct Mol Biol
          <year>2008</year>
<volume>15</volume>
<fpage>422</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.1404</pub-id>
<pub-id pub-id-type="pmid">18376415</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ploug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ronne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Behrendt</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dano</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol</article-title>
<source/>J Biol Chem
          <year>1991</year>
<volume>266</volume>
<fpage>1926</fpage>
<lpage>1933</lpage>
<pub-id pub-id-type="pmid">1846368</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mondino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>uPA and uPAR in fibrinolysis, immunity and pathology</article-title>
<source/>Trends Immunol
          <year>2004</year>
<volume>25</volume>
<fpage>450</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="doi">10.1016/j.it.2004.06.004</pub-id>
<pub-id pub-id-type="pmid">15275645</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Behrendt</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dano</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor</article-title>
<source/>J Biol Chem
          <year>1991</year>
<volume>266</volume>
<fpage>12752</fpage>
<lpage>12758</lpage>
<pub-id pub-id-type="pmid">1829461</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vassalli</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wohlwend</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Belin</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system</article-title>
<source/>Curr Top Microbiol Immunol
          <year>1992</year>
<volume>181</volume>
<fpage>65</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1007/978-3-642-77377-8_3</pub-id>
<pub-id pub-id-type="pmid">1330446</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Waltz</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Drummond</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>HA</given-names>
</name>
</person-group>
<article-title>Identification of the urokinase receptor as an adhesion receptor for vitronectin</article-title>
<source/>J Biol Chem
          <year>1994</year>
<volume>269</volume>
<fpage>32380</fpage>
<lpage>32388</lpage>
<pub-id pub-id-type="pmid">7528215</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barinka</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Callahan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bdeir</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural basis of interaction between urokinase-type plasminogen activator and its receptor</article-title>
<source/>J Mol Biol
          <year>2006</year>
<volume>363</volume>
<fpage>482</fpage>
<lpage>495</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2006.08.063</pub-id>
<pub-id pub-id-type="pmid">16979660</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gardsvoll</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kriegbaum</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Behrendt</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Engelholm</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ostergaard</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<fpage>33544</fpage>
<lpage>33556</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.220087</pub-id>
<pub-id pub-id-type="pmid">21799009</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gandhi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gardsvoll</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation</article-title>
<source/>J Mol Biol
          <year>2015</year>
<volume>427</volume>
<fpage>1389</fpage>
<lpage>1403</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2015.01.022</pub-id>
<pub-id pub-id-type="pmid">25659907</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Andolfo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Santovito</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Iuzzolino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sidenius</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions</article-title>
<source/>EMBO J
          <year>2003</year>
<volume>22</volume>
<fpage>5994</fpage>
<lpage>6003</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/cdg588</pub-id>
<pub-id pub-id-type="pmid">14609946</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caiolfa</surname>
<given-names>VR</given-names>
</name>
<name>
<surname>Zamai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Malengo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Andolfo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Sutin</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Monomer dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies</article-title>
<source/>J Cell Biol
          <year>2007</year>
<volume>179</volume>
<fpage>1067</fpage>
<lpage>1082</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200702151</pub-id>
<pub-id pub-id-type="pmid">18056417</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaus</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Le Lay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Balasubramanian</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Integrin-mediated adhesion regulates membrane order</article-title>
<source/>J Cell Biol
          <year>2006</year>
<volume>174</volume>
<fpage>725</fpage>
<lpage>734</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200603034</pub-id>
<pub-id pub-id-type="pmid">16943184</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madsen</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Ferraris</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Andolfo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sidenius</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>uPAR-induced cell adhesion and migration: vitronectin provides the key</article-title>
<source/>J Cell Biol
          <year>2007</year>
<volume>177</volume>
<fpage>927</fpage>
<lpage>939</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200612058</pub-id>
<pub-id pub-id-type="pmid">17548516</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degryse</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Resnati</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Czekay</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Loskutoff</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor</article-title>
<source/>J Biol Chem
          <year>2005</year>
<volume>280</volume>
<fpage>24792</fpage>
<lpage>24803</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M413954200</pub-id>
<pub-id pub-id-type="pmid">15863511</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaurasia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Aguirre-Ghiso</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Gardsvoll</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ploug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ossowski</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth</article-title>
<source/>J Biol Chem
          <year>2006</year>
<volume>281</volume>
<fpage>14852</fpage>
<lpage>14863</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M512311200</pub-id>
<pub-id pub-id-type="pmid">16547007</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Brumwell</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins</article-title>
<source/>J Cell Sci
          <year>2008</year>
<volume>121</volume>
<fpage>3747</fpage>
<lpage>3756</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.029769</pub-id>
<pub-id pub-id-type="pmid">18940913</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grove</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Southern</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>White</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Paruchuri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Harel</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts</article-title>
<source/>J Biol Chem
          <year>2014</year>
<volume>289</volume>
<fpage>12791</fpage>
<lpage>12804</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.498576</pub-id>
<pub-id pub-id-type="pmid">24644284</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>May</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Kanse</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lund</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Gisler</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Imhof</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Preissner</surname>
<given-names>KT</given-names>
</name>
</person-group>
<article-title>Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo</article-title>
<source/>J Exp Med
          <year>1998</year>
<volume>188</volume>
<fpage>1029</fpage>
<lpage>1037</lpage>
<pub-id pub-id-type="doi">10.1084/jem.188.6.1029</pub-id>
<pub-id pub-id-type="pmid">9743521</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Majdic</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ronne</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells</article-title>
<source/>Blood.
          <year>1996</year>
<volume>88</volume>
<fpage>3185</fpage>
<lpage>3194</lpage>
<pub-id pub-id-type="doi">10.1182/blood.V88.8.3185.bloodjournal8883185</pub-id>
<pub-id pub-id-type="pmid">8874219</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sitrin</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Todd</surname>
<given-names>RF</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Albrecht</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gyetko</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes</article-title>
<source/>J Clin Invest
          <year>1996</year>
<volume>97</volume>
<fpage>1942</fpage>
<lpage>1951</lpage>
<pub-id pub-id-type="doi">10.1172/jci118626</pub-id>
<pub-id pub-id-type="pmid">8621779</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Role of the lectin domain of mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion</article-title>
<source/>Immunol Res
          <year>2002</year>
<volume>25</volume>
<fpage>219</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1385/ir:25:3:219</pub-id>
<pub-id pub-id-type="pmid">12018461</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function</article-title>
<source/>J Biol Chem
          <year>2000</year>
<volume>275</volume>
<fpage>10228</fpage>
<lpage>10234</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.275.14.10228</pub-id>
<pub-id pub-id-type="pmid">10744708</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pliyev</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Antonova</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Menshikov</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration</article-title>
<source/>Mol Immunol
          <year>2011</year>
<volume>48</volume>
<fpage>1168</fpage>
<lpage>1177</lpage>
<pub-id pub-id-type="doi">10.1016/j.molimm.2011.02.011</pub-id>
<pub-id pub-id-type="pmid">21470685</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pliyev</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Arefieva</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Menshikov</surname>
<given-names>MY</given-names>
</name>
</person-group>
<article-title>Urokinase receptor (uPAR) regulates complement receptor 3 (CR3)-mediated neutrophil phagocytosis</article-title>
<source/>Biochem Biophys Res Commun
          <year>2010</year>
<volume>397</volume>
<fpage>277</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2010.05.100</pub-id>
<pub-id pub-id-type="pmid">20580686</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Donate</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Juarez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (alphaM)</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e85349</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0085349</pub-id>
<pub-id pub-id-type="pmid">24465541</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguirre-Ghiso</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mignatti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kovalski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ossowski</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo</article-title>
<source/>Mol Biol Cell
          <year>2001</year>
<volume>12</volume>
<fpage>863</fpage>
<lpage>879</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.12.4.863</pub-id>
<pub-id pub-id-type="pmid">11294892</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguirre Ghiso</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kovalski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ossowski</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling</article-title>
<source/>J Cell Biol
          <year>1999</year>
<volume>147</volume>
<fpage>89</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.147.1.89</pub-id>
<pub-id pub-id-type="pmid">10508858</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mukhopadhyay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways</article-title>
<source/>J Biol Chem
          <year>2006</year>
<volume>281</volume>
<fpage>13021</fpage>
<lpage>13029</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M508526200</pub-id>
<pub-id pub-id-type="pmid">16510444</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Robillard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kugler</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells</article-title>
<source/>J Biol Chem
          <year>2007</year>
<volume>282</volume>
<fpage>3929</fpage>
<lpage>3939</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M607989200</pub-id>
<pub-id pub-id-type="pmid">17145753</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Czekay</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Robillard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kugler</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding</article-title>
<source/>J Cell Biol
          <year>2005</year>
<volume>168</volume>
<fpage>501</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200404112</pub-id>
<pub-id pub-id-type="pmid">15684035</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferraris</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Buttiglione</surname>
<given-names>V</given-names>
</name>
<name>
<surname>De Lorenzi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Piontini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galluzzi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins</article-title>
<source/>EMBO J
          <year>2014</year>
<volume>33</volume>
<fpage>2458</fpage>
<lpage>2472</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201387611</pub-id>
<pub-id pub-id-type="pmid">25168639</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Margheri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Luciani</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Taddei</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Giannoni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Laurenzana</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Biagioni</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style</article-title>
<source/>Oncotarget
          <year>2014</year>
<volume>5</volume>
<fpage>1538</fpage>
<lpage>1553</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.1754</pub-id>
<pub-id pub-id-type="pmid">24681666</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Marra</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180</article-title>
<source/>J Cell Biol
          <year>2008</year>
<volume>182</volume>
<fpage>777</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200712050</pub-id>
<pub-id pub-id-type="pmid">18725541</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adachi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lakka</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Chandrasekar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yanamandra</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gondi</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Mohanam</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes</article-title>
<source/>J Biol Chem
          <year>2001</year>
<volume>276</volume>
<fpage>47171</fpage>
<lpage>47177</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M104334200</pub-id>
<pub-id pub-id-type="pmid">11572856</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Mahalingham</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Borrelli</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Rui</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment</article-title>
<source/>J Cell Biol
          <year>2009</year>
<volume>186</volume>
<fpage>589</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200905085</pub-id>
<pub-id pub-id-type="pmid">19704023</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Mohamedali</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cheruku</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sowmya</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of the interaction between heterodimeric alphavbeta6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics</article-title>
<source/>J Proteome Res
          <year>2014</year>
<volume>13</volume>
<fpage>5956</fpage>
<lpage>5964</lpage>
<pub-id pub-id-type="doi">10.1021/pr500849x</pub-id>
<pub-id pub-id-type="pmid">25318615</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nykjaer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Cremona</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Pardi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Andreasen</surname>
<given-names>PA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alpha-2 macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor</article-title>
<source/>J Cell Biol
          <year>1995</year>
<volume>131</volume>
<fpage>1609</fpage>
<lpage>1622</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.131.6.1609</pub-id>
<pub-id pub-id-type="pmid">8522616</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Czekay</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Kuemmel</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Orlando</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Farquhar</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity</article-title>
<source/>Mol Biol Cell
          <year>2001</year>
<volume>12</volume>
<fpage>1467</fpage>
<lpage>1479</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.12.5.1467</pub-id>
<pub-id pub-id-type="pmid">11359936</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degryse</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sier</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Resnati</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Conese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor</article-title>
<source/>FEBS Lett
          <year>2001</year>
<volume>505</volume>
<fpage>249</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1016/s0014-5793(01)02797-1</pub-id>
<pub-id pub-id-type="pmid">11566185</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nykjaer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Conese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cremona</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gliemann</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes</article-title>
<source/>EMBO J
          <year>1997</year>
<volume>16</volume>
<fpage>2610</fpage>
<lpage>2620</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/16.10.2610</pub-id>
<pub-id pub-id-type="pmid">9184208</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidenius</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sier</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo</article-title>
<source/>FEBS Lett
          <year>2000</year>
<volume>475</volume>
<fpage>52</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/s0014-5793(00)01624-0</pub-id>
<pub-id pub-id-type="pmid">10854857</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilhelm</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Weidle</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hohl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rettenberger</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Graeff</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells</article-title>
<source/>FEBS Lett
          <year>1994</year>
<volume>337</volume>
<fpage>131</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/0014-5793(94)80259-9</pub-id>
<pub-id pub-id-type="pmid">8287966</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thuno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Macho</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eugen-Olsen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>suPAR: the molecular crystal ball</article-title>
<source/>Dis Markers
          <year>2009</year>
<volume>27</volume>
<fpage>157</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.3233/dma-2009-0657</pub-id>
<pub-id pub-id-type="pmid">19893210</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montuori</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Carriero</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Salzano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ragno</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The cleavage of the urokinase receptor regulates its multiple functions</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>46932</fpage>
<lpage>46939</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M207494200</pub-id>
<pub-id pub-id-type="pmid">12297505</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Resnati</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pallavicini</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Oppenheim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Serhan</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2002</year>
<volume>99</volume>
<fpage>1359</fpage>
<lpage>1364</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.022652999</pub-id>
<pub-id pub-id-type="pmid">11818541</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Paulis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Montuori</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Prevete</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fiorentino</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Visconte</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2</article-title>
<source/>J Immun (Baltimore, Md: 1950)
          <year>2004</year>
<volume>173</volume>
<fpage>5739</fpage>
<lpage>5748</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.173.9.5739</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benjamin</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Muntner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bittencourt</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>AP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heart disease and stroke statistics-2019 update: a report from the American Heart Association</article-title>
<source/>Circulation.
          <year>2019</year>
<volume>139</volume>
<fpage>e56</fpage>
<lpage>e528</lpage>
<pub-id pub-id-type="doi">10.1161/cir.0000000000000659</pub-id>
<pub-id pub-id-type="pmid">30700139</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavakoli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vashist</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sadeghi</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Molecular imaging of plaque vulnerability</article-title>
<source/>J Nucl Cardiol
          <year>2014</year>
<volume>21</volume>
<fpage>1112</fpage>
<lpage>1128</lpage>
<pub-id pub-id-type="doi">10.1007/s12350-014-9959-4</pub-id>
<pub-id pub-id-type="pmid">25124827</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anwaier</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>A review of molecular imaging of atherosclerosis and the potential application of dendrimer in imaging of plaque</article-title>
<source/>Int J Nanomedicine
          <year>2017</year>
<volume>12</volume>
<fpage>7681</fpage>
<lpage>7693</lpage>
<pub-id pub-id-type="doi">10.2147/ijn.s142385</pub-id>
<pub-id pub-id-type="pmid">29089763</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virmani</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Farb</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kolodgie</surname>
<given-names>FD</given-names>
</name>
</person-group>
<article-title>Pathology of the vulnerable plaque</article-title>
<source/>J Am Coll Cardiol
          <year>2006</year>
<volume>47</volume>
<fpage>C13</fpage>
<lpage>C18</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2005.10.065</pub-id>
<pub-id pub-id-type="pmid">16631505</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarkin</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Dweck</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Takx</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Tawakol</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging atherosclerosis</article-title>
<source/>Circ Res
          <year>2016</year>
<volume>118</volume>
<fpage>750</fpage>
<lpage>769</lpage>
<pub-id pub-id-type="doi">10.1161/circresaha.115.306247</pub-id>
<pub-id pub-id-type="pmid">26892971</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bala</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Broisat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lahoutte</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hernot</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Translating molecular imaging of the vulnerable plaque-a vulnerable project?</article-title>
<source/>Mol Imaging and Biology
          <year>2018</year>
<volume>20</volume>
<fpage>337</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="doi">10.1007/s11307-017-1147-x</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rafieian-Kopaei</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Setorki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Doudi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baradaran</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nasri</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Atherosclerosis: process, indicators, risk factors and new hopes</article-title>
<source/>Int J Prev Med
          <year>2014</year>
<volume>5</volume>
<fpage>927</fpage>
<lpage>946</lpage>
<pub-id pub-id-type="pmid">25489440</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Noels</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Atherosclerosis: current pathogenesis and therapeutic options</article-title>
<source/>Nat Med
          <year>2011</year>
<volume>17</volume>
<fpage>1410</fpage>
<lpage>1422</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2538</pub-id>
<pub-id pub-id-type="pmid">22064431</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuhrman</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The urokinase system in the pathogenesis of atherosclerosis</article-title>
<source/>Atherosclerosis.
          <year>2012</year>
<volume>222</volume>
<fpage>8</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.10.044</pub-id>
<pub-id pub-id-type="pmid">22137664</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jurk</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lorenz</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hepatic overexpression of soluble urokinase receptor (uPAR) suppresses diet-induced atherosclerosis in low-density lipoprotein receptor-deficient (LDLR-/-) mice</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0131854</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0131854</pub-id>
<pub-id pub-id-type="pmid">26313756</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>May</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kanse</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Chavakis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Schomig</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction</article-title>
<source/>Blood.
          <year>2002</year>
<volume>100</volume>
<fpage>3611</fpage>
<lpage>3617</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2002-03-0778</pub-id>
<pub-id pub-id-type="pmid">12393744</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Johns</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morser</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dole</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Greaves</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>GG</given-names>
</name>
</person-group>
<article-title>Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice</article-title>
<source/>J Cell Physiol
          <year>2005</year>
<volume>204</volume>
<fpage>73</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.20262</pub-id>
<pub-id pub-id-type="pmid">15573379</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuhrman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nitzan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Karry</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Volkova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dumler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Aviram</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner</article-title>
<source/>Atherosclerosis.
          <year>2007</year>
<volume>195</volume>
<fpage>e108</fpage>
<lpage>e116</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2007.06.025</pub-id>
<pub-id pub-id-type="pmid">17681345</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohwaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bujo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>A secreted soluble form of LR11, specifically expressed in intimal smooth muscle cells, accelerates formation of lipid-laden macrophages</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2007</year>
<volume>27</volume>
<fpage>1050</fpage>
<lpage>1056</lpage>
<pub-id pub-id-type="doi">10.1161/atvbaha.106.137091</pub-id>
<pub-id pub-id-type="pmid">17332490</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Maurer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Medcalf</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation</article-title>
<source/>Blood.
          <year>2002</year>
<volume>99</volume>
<fpage>2810</fpage>
<lpage>2818</lpage>
<pub-id pub-id-type="doi">10.1182/blood.v99.8.2810</pub-id>
<pub-id pub-id-type="pmid">11929770</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukhina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stepanova</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Traktouev</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Poliakov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Beabealashvilly</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gursky</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis</article-title>
<source/>J Biol Chem
          <year>2000</year>
<volume>275</volume>
<fpage>16450</fpage>
<lpage>16458</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M909080199</pub-id>
<pub-id pub-id-type="pmid">10749881</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stepanova</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jerke</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Sagach</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lindschau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dietz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>10265</fpage>
<lpage>10272</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109057200</pub-id>
<pub-id pub-id-type="pmid">11756447</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kunigal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kusch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jerke</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Monocyte-expressed urokinase inhibits vascular smooth muscle cell growth by activating Stat1</article-title>
<source/>Blood.
          <year>2003</year>
<volume>102</volume>
<fpage>4377</fpage>
<lpage>4383</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2002-12-3872</pub-id>
<pub-id pub-id-type="pmid">12920039</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kusch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lutter</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dietz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lipp</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Monocyte-expressed urokinase regulates human vascular smooth muscle cell migration in a coculture model</article-title>
<source/>Biol Chem
          <year>2002</year>
<volume>383</volume>
<fpage>217</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1515/bc.2002.022</pub-id>
<pub-id pub-id-type="pmid">11928816</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hilfiker-Kleiner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fuhrman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dumler</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4</article-title>
<source/>J Mol Cell Cardiol
          <year>2014</year>
<volume>66</volume>
<fpage>72</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.11.005</pub-id>
<pub-id pub-id-type="pmid">24239845</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Limbourg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kiyan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Limbourg</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Ovsianikov</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2012</year>
<volume>32</volume>
<fpage>110</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1161/atvbaha.111.234369</pub-id>
<pub-id pub-id-type="pmid">22075245</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallabhaneni</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kiyan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shushakova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dumler</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase receptor mediates mobilization, migration, and differentiation of mesenchymal stem cells</article-title>
<source/>Cardiovasc Res
          <year>2011</year>
<volume>90</volume>
<fpage>113</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvq362</pub-id>
<pub-id pub-id-type="pmid">21088115</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dumler</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts</article-title>
<source/>Biochem J
          <year>2009</year>
<volume>423</volume>
<fpage>343</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="doi">10.1042/bj20090447</pub-id>
<pub-id pub-id-type="pmid">19691446</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kusch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dietz</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor</article-title>
<source/>Atherosclerosis.
          <year>2007</year>
<volume>195</volume>
<fpage>254</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.12.030</pub-id>
<pub-id pub-id-type="pmid">17275828</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noda-Heiny</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Daugherty</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sobel</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>Augmented urokinase receptor expression in atheroma</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>1995</year>
<volume>15</volume>
<fpage>37</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1161/01.ATV.15.1.37</pub-id>
<pub-id pub-id-type="pmid">7749814</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalbasi Anaraki</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Patecki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kiyan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dumler</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-kappaB pathway in osteoclasts</article-title>
<source/>J Bone Min Res
          <year>2015</year>
<volume>30</volume>
<fpage>379</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1002/jbmr.2350</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalbasi Anaraki</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Patecki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Larmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tkachuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jurk</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase receptor mediates osteogenic differentiation of mesenchymal stem cells and vascular calcification via the complement C5a receptor</article-title>
<source/>Stem Cells Dev
          <year>2014</year>
<volume>23</volume>
<fpage>352</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1089/scd.2013.0318</pub-id>
<pub-id pub-id-type="pmid">24192237</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farris</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<fpage>22665</fpage>
<lpage>22677</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.202135</pub-id>
<pub-id pub-id-type="pmid">21536666</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salame</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Samani</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>Masood I, deBono DP. Expression of the plasminogen activator system in the human vascular wall</article-title>
<source/>Atherosclerosis.
          <year>2000</year>
<volume>152</volume>
<fpage>19</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/s0021-9150(99)00441-4</pub-id>
<pub-id pub-id-type="pmid">10996335</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svensson</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Hagg</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Ryndel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wiklund</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Karlstrom</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis</article-title>
<source/>Int J Mol Med
          <year>2008</year>
<volume>22</volume>
<fpage>459</fpage>
<lpage>464</lpage>
<pub-id pub-id-type="pmid">18813852</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>WQ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Urokinase receptor surface expression regulates monocyte migration and is associated with accelerated atherosclerosis</article-title>
<source/>Int J Cardiol
          <year>2012</year>
<volume>161</volume>
<fpage>103</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijcard.2011.12.094</pub-id>
<pub-id pub-id-type="pmid">22236514</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raghunath</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Tomaszewski</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Barnathan</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Plasminogen activator system in human coronary atherosclerosis</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>1995</year>
<volume>15</volume>
<fpage>1432</fpage>
<lpage>1443</lpage>
<pub-id pub-id-type="doi">10.1161/01.ATV.15.9.1432</pub-id>
<pub-id pub-id-type="pmid">7670959</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okada</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Golden</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Raghunath</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Tomaszewski</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>David</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo</article-title>
<source/>Thromb Haemost
          <year>1998</year>
<volume>80</volume>
<fpage>140</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1055/s-0037-1615153</pub-id>
<pub-id pub-id-type="pmid">9684800</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steins</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Padro</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schwaenen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mesters</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Berdel</surname>
<given-names>WE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions</article-title>
<source/>Blood Coagul Fibrinolysis
          <year>2004</year>
<volume>15</volume>
<fpage>383</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="doi">10.1097/01.mbc.0000114441.59147.56</pub-id>
<pub-id pub-id-type="pmid">15205586</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quax</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Lamfers</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lardenoye</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Grimbergen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Slomp</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels</article-title>
<source/>Circulation.
          <year>2001</year>
<volume>103</volume>
<fpage>562</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1161/01.cir.103.4.562</pub-id>
<pub-id pub-id-type="pmid">11157723</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamfers</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Grimbergen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Aalders</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Havenga</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Huisman</surname>
<given-names>LG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1</article-title>
<source/>Circ Res
          <year>2002</year>
<volume>91</volume>
<fpage>945</fpage>
<lpage>952</lpage>
<pub-id pub-id-type="doi">10.1161/01.res.0000041418.51906.57</pub-id>
<pub-id pub-id-type="pmid">12433840</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eefting</surname>
<given-names>D</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Grimbergen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Karper</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>van Bockel</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Quax</surname>
<given-names>PH</given-names>
</name>
</person-group>
<article-title>In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor</article-title>
<source/>J Vasc Surg
          <year>2010</year>
<volume>51</volume>
<fpage>429</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1016/j.jvs.2009.09.026</pub-id>
<pub-id pub-id-type="pmid">20036101</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamfers</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lardenoye</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Aalders</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Engelse</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Grimbergen</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI</article-title>
<source/>Gene Ther
          <year>2001</year>
<volume>8</volume>
<fpage>534</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1038/sj.gt.3301437</pub-id>
<pub-id pub-id-type="pmid">11319620</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eefting</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Seghers</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Grimbergen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>de Boer</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Lardenoye</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease</article-title>
<source/>Cardiovasc Res
          <year>2010</year>
<volume>88</volume>
<fpage>367</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvq203</pub-id>
<pub-id pub-id-type="pmid">20562095</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crowson</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Matteson</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Myasoedova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Michet</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Ernste</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Warrington</surname>
<given-names>KJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases</article-title>
<source/>Arthritis Rheum
          <year>2011</year>
<volume>63</volume>
<fpage>633</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.1002/art.30155</pub-id>
<pub-id pub-id-type="pmid">21360492</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colebatch</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Ostergaard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van der Heijde</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Balint</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>D’Agostino</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis</article-title>
<source/>Ann Rheum Dis
          <year>2013</year>
<volume>72</volume>
<fpage>804</fpage>
<lpage>814</lpage>
<pub-id pub-id-type="doi">10.1136/annrheumdis-2012-203158</pub-id>
<pub-id pub-id-type="pmid">23520036</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wunder</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Gay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Funk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Muller-Ladner</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Molecular imaging: novel tools in visualizing rheumatoid arthritis</article-title>
<source/>Rheumatology (Oxford)
          <year>2005</year>
<volume>44</volume>
<fpage>1341</fpage>
<lpage>1349</lpage>
<pub-id pub-id-type="doi">10.1093/rheumatology/keh709</pub-id>
<pub-id pub-id-type="pmid">15972356</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Put</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Westhovens</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lahoutte</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matthys</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques</article-title>
<source/>Arthritis Res Ther.
          <year>2014</year>
<volume>16</volume>
<fpage>208</fpage>
<pub-id pub-id-type="doi">10.1186/ar4542</pub-id>
<pub-id pub-id-type="pmid">25099015</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malviya</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chianelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scopinaro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dierckx</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Signore</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2010</year>
<volume>37</volume>
<fpage>386</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-009-1272-0</pub-id>
<pub-id pub-id-type="pmid">19777175</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McInnes</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Schett</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Pathogenetic insights from the treatment of rheumatoid arthritis</article-title>
<source/>Lancet.
          <year>2017</year>
<volume>389</volume>
<fpage>2328</fpage>
<lpage>2337</lpage>
<pub-id pub-id-type="doi">10.1016/s0140-6736(17)31472-1</pub-id>
<pub-id pub-id-type="pmid">28612747</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinesh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rasool</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>uPA/uPAR signaling in rheumatoid arthritis: shedding light on its mechanism of action</article-title>
<source/>Pharmacol Res
          <year>2018</year>
<volume>134</volume>
<fpage>31</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2018.05.016</pub-id>
<pub-id pub-id-type="pmid">29859810</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serrati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Margheri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Muller-Ladner</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Benucci</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduction of in vitro invasion and in vivo cartilage degradation in a SCID mouse model by loss of function of the fibrinolytic system of rheumatoid arthritis synovial fibroblasts</article-title>
<source/>Arthritis Rheum
          <year>2011</year>
<volume>63</volume>
<fpage>2584</fpage>
<lpage>2594</lpage>
<pub-id pub-id-type="doi">10.1002/art.30439</pub-id>
<pub-id pub-id-type="pmid">21547898</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nossent</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pavlos</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies</article-title>
<source/>Bone research
          <year>2018</year>
<volume>6</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.1038/s41413-018-0016-9</pub-id>
<pub-id pub-id-type="pmid">29736302</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szekanecz</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Haines</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues</article-title>
<source/>J Clin Pathol
          <year>1997</year>
<volume>50</volume>
<fpage>314</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1136/jcp.50.4.314</pub-id>
<pub-id pub-id-type="pmid">9215148</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almholt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hebsgaard</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Nansen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pass</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rono</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antibody-mediated neutralization of uPA proteolytic function reduces disease progression in mouse arthritis models</article-title>
<source/>J Immunol
          <year>2018</year>
<volume>200</volume>
<fpage>957</fpage>
<lpage>965</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1701317</pub-id>
<pub-id pub-id-type="pmid">29282305</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pliyev</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Menshikov</surname>
<given-names>MY</given-names>
</name>
</person-group>
<article-title>Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis</article-title>
<source/>Inflammation.
          <year>2010</year>
<volume>33</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1007/s10753-009-9152-0</pub-id>
<pub-id pub-id-type="pmid">19756998</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fibbi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pucci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Serni</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Cerinic</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Del Rosso</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro</article-title>
<source/>Proc Assoc Am Physicians
          <year>1998</year>
<volume>110</volume>
<fpage>340</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="pmid">9686682</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baran</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mollers</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Ekwall</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Bjersing</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Survivin is an essential mediator of arthritis interacting with urokinase signalling</article-title>
<source/>J Cell Mol Med
          <year>2009</year>
<volume>13</volume>
<fpage>3797</fpage>
<lpage>3808</lpage>
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00721.x</pub-id>
<pub-id pub-id-type="pmid">19298527</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchheimer</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Modulation of receptor bound urokinase-type plasminogen activator on human monocytes by non-steroidal antiinflammatory drugs</article-title>
<source/>Scand J Rheumatol
          <year>1993</year>
<volume>22</volume>
<fpage>53</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.3109/03009749309095115</pub-id>
<pub-id pub-id-type="pmid">8386851</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nonaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hamanishi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis</article-title>
<source/>J Rheumatol
          <year>2000</year>
<volume>27</volume>
<fpage>997</fpage>
<lpage>1004</lpage>
<pub-id pub-id-type="pmid">10782829</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nonaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sohen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hamanishi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Comparison of the inhibitory effects of two types (90 kDa and 190 kDa) of hyaluronic acid on the expression of fibrinolytic factors in human synovial fibroblasts</article-title>
<source/>Mod Rheumatol
          <year>2002</year>
<volume>12</volume>
<fpage>160</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.3109/s101650200027</pub-id>
<pub-id pub-id-type="pmid">24383905</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guiducci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Del Rosso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cinelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Margheri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>D’Alessio</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fibbi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rheumatoid synovial fibroblasts constitutively express the fibrinolytic pattern of invasive tumor-like cells</article-title>
<source/>Clin Exp Rheumatol
          <year>2005</year>
<volume>23</volume>
<fpage>364</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="pmid">15971425</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Rosso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fibbi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Magnelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pucci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grappone</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modulation of urokinase receptors on human synovial cells and osteoarthritic chondrocytes by diacetylrhein</article-title>
<source/>Int J Tissue React
          <year>1990</year>
<volume>12</volume>
<fpage>91</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">2170288</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchheimer</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Remold</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Wanivenhaus</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis</article-title>
<source/>Arthritis Rheum
          <year>1991</year>
<volume>34</volume>
<fpage>1430</fpage>
<lpage>1433</lpage>
<pub-id pub-id-type="doi">10.1002/art.1780341114</pub-id>
<pub-id pub-id-type="pmid">1659424</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belcher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fawthrop</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bunning</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees</article-title>
<source/>Ann Rheum Dis
          <year>1996</year>
<volume>55</volume>
<fpage>230</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1136/ard.55.4.230</pub-id>
<pub-id pub-id-type="pmid">8733439</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ronday</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Van Muijen</surname>
<given-names>GN</given-names>
</name>
<name>
<surname>Pruszczynski</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Dolhain</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Van Langelaan</surname>
<given-names>EJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis</article-title>
<source/>Br J Rheumatol
          <year>1996</year>
<volume>35</volume>
<fpage>416</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1093/rheumatology/35.5.416</pub-id>
<pub-id pub-id-type="pmid">8646430</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Busso</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Peclat</surname>
<given-names>V</given-names>
</name>
<name>
<surname>So</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sappino</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints</article-title>
<source/>Ann Rheum Dis
          <year>1997</year>
<volume>56</volume>
<fpage>550</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="doi">10.1136/ard.56.9.550</pub-id>
<pub-id pub-id-type="pmid">9370880</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerinic</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Generini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Partsch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pignone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Konttinen</surname>
<given-names>YT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface</article-title>
<source/>Life Sci
          <year>1998</year>
<volume>63</volume>
<fpage>441</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1016/s0024-3205(98)00293-8</pub-id>
<pub-id pub-id-type="pmid">9718068</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thornton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Raghu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Frederick</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Palumbo</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Mullins</surname>
<given-names>ES</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells</article-title>
<source/>Blood advances
          <year>2017</year>
<volume>1</volume>
<fpage>545</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="doi">10.1182/bloodadvances.2016004002</pub-id>
<pub-id pub-id-type="pmid">29296974</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tarkowski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carmeliet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bokarewa</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis</article-title>
<source/>Arthritis Res Ther
          <year>2003</year>
<volume>5</volume>
<fpage>R9</fpage>
<lpage>r17</lpage>
<pub-id pub-id-type="doi">10.1186/ar606</pub-id>
<pub-id pub-id-type="pmid">12716448</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ishisaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miyashita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>The blocking of uPAR suppresses lipopolysaccharide-induced inflammatory osteoclastogenesis and the resultant bone loss through attenuation of integrin beta3/Akt pathway</article-title>
<source/>Immunity, inflammation and disease.
          <year>2016</year>
<volume>4</volume>
<fpage>338</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="doi">10.1002/iid3.116</pub-id>
<pub-id pub-id-type="pmid">27621816</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ishisaki</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>uPA-derived peptide, A6 is involved in the suppression of lipopolysaccaride-promoted inflammatory osteoclastogenesis and the resultant bone loss</article-title>
<source/>Immunity, inflammation and disease
          <year>2017</year>
<volume>5</volume>
<fpage>289</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1002/iid3.169</pub-id>
<pub-id pub-id-type="pmid">28493442</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apparailly</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bouquet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Millet</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Noel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jacquet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Opolon</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis</article-title>
<source/>Gene Ther
          <year>2002</year>
<volume>9</volume>
<fpage>192</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1038/sj.gt.3301628</pub-id>
<pub-id pub-id-type="pmid">11859422</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Laan</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Pap</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ronday</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Grimbergen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Huisman</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>TeKoppele</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor</article-title>
<source/>Arthritis Rheum
          <year>2000</year>
<volume>43</volume>
<fpage>1710</fpage>
<lpage>1718</lpage>
<pub-id pub-id-type="doi">10.1002/1529-0131(200008)43:8&lt;1710::AID-ANR6&gt;3.0.CO;2-Y</pub-id>
<pub-id pub-id-type="pmid">10943860</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Rosso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cinelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guiducci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pignone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fibbi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Margheri</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes</article-title>
<source/>Rheumatology (Oxford)
          <year>2005</year>
<volume>44</volume>
<fpage>1255</fpage>
<lpage>1262</lpage>
<pub-id pub-id-type="doi">10.1093/rheumatology/kei006</pub-id>
<pub-id pub-id-type="pmid">15998634</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koga</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kawashiri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population</article-title>
<source/>Clin Exp Rheumatol
          <year>2011</year>
<volume>29</volume>
<fpage>811</fpage>
<lpage>815</lpage>
<pub-id pub-id-type="pmid">22011479</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buckley</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Kelso</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ranson</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The urokinase plasminogen activation system in rheumatoid arthritis: pathophysiological roles and prospective therapeutic targets</article-title>
<source/>Curr Drug Targets
          <year>2019</year>
<volume>20</volume>
<fpage>970</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="doi">10.2174/1389450120666181204164140</pub-id>
<pub-id pub-id-type="pmid">30516104</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Howes</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Molecular imaging as a guide for the treatment of central nervous system disorders</article-title>
<source/>Dialogues Clin Neurosci
          <year>2013</year>
<volume>15</volume>
<fpage>315</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="pmid">24174903</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases</article-title>
<source/>Quant Imaging Med Surg
          <year>2015</year>
<volume>5</volume>
<fpage>433</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="doi">10.3978/j.issn.2223-4292.2015.03.16</pub-id>
<pub-id pub-id-type="pmid">26029646</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hargreaves</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hoppin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sevigny</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chiao</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Klimas</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Optimizing central nervous system drug development using molecular imaging</article-title>
<source/>Clin Pharmacol Ther
          <year>2015</year>
<volume>98</volume>
<fpage>47</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1002/cpt.132</pub-id>
<pub-id pub-id-type="pmid">25869938</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohnen</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Kanel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular imaging of the cholinergic system in Parkinson’s disease</article-title>
<source/>Int Rev Neurobiol
          <year>2018</year>
<volume>141</volume>
<fpage>211</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1016/bs.irn.2018.07.027</pub-id>
<pub-id pub-id-type="pmid">30314597</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merino</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jeanneret</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase-type plasminogen activator (uPA) binding to the uPA receptor (uPAR) promotes axonal regeneration in the central nervous system</article-title>
<source/>J Biol Chem
          <year>2017</year>
<volume>292</volume>
<fpage>2741</fpage>
<lpage>2753</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M116.761650</pub-id>
<pub-id pub-id-type="pmid">27986809</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lino</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fiore</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rapacioli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Teruel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Scicolone</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>uPA-uPAR molecular complex is involved in cell signaling during neuronal migration and neuritogenesis</article-title>
<source/>Developmental Dynamics
          <year>2014</year>
<volume>243</volume>
<fpage>676</fpage>
<lpage>689</lpage>
<pub-id pub-id-type="doi">10.1002/dvdy.24114</pub-id>
<pub-id pub-id-type="pmid">24481918</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farias-Eisner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vician</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rabbani</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Herschman</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>The urokinase plasminogen activator receptor (UPAR) is preferentially induced by nerve growth factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiation</article-title>
<source/>J Neurosci
          <year>2000</year>
<volume>20</volume>
<fpage>230</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.20-01-00230.2000</pub-id>
<pub-id pub-id-type="pmid">10627600</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rubina</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sysoeva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rysenkova</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Klimovich</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Plekhanova</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching</article-title>
<source/>Eur J Cell Biol
          <year>2016</year>
<volume>95</volume>
<fpage>295</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejcb.2016.05.003</pub-id>
<pub-id pub-id-type="pmid">27324124</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Del Bigio</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Hosain</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Altumbabic</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Localization of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse forebrain during postnatal development</article-title>
<source/>Int J Dev Neurosci
          <year>1999</year>
<volume>17</volume>
<fpage>387</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1016/S0736-5748(99)00031-3</pub-id>
<pub-id pub-id-type="pmid">10479073</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayden</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Seeds</surname>
<given-names>NW</given-names>
</name>
</person-group>
<article-title>Modulated expression of plasminogen activator system components in cultured cells from dissociated mouse dorsal root ganglia</article-title>
<source/>J Neurosci
          <year>1996</year>
<volume>16</volume>
<fpage>2307</fpage>
<lpage>2317</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.16-07-02307.1996</pub-id>
<pub-id pub-id-type="pmid">8601810</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>D’Oronzio</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Garbett</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Mirnics</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disruption of cerebral cortex MET signaling in autism spectrum disorder</article-title>
<source/>Ann Neurol
          <year>2007</year>
<volume>62</volume>
<fpage>243</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21180</pub-id>
<pub-id pub-id-type="pmid">17696172</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sutcliffe</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder</article-title>
<source/>Autism Research
          <year>2008</year>
<volume>1</volume>
<fpage>159</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1002/aur.27</pub-id>
<pub-id pub-id-type="pmid">19360663</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lahtinen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huusko</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Myohanen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lehtivarjo</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Pellinen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Turunen</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus</article-title>
<source/>Neuroscience.
          <year>2009</year>
<volume>163</volume>
<fpage>316</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.06.019</pub-id>
<pub-id pub-id-type="pmid">19527776</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Powell</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Stanwood</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Noebels</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction</article-title>
<source/>J Neurosci
          <year>2003</year>
<volume>23</volume>
<fpage>622</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-02-00622.2003</pub-id>
<pub-id pub-id-type="pmid">12533622</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Disruption of interneuron development</article-title>
<source/>Epilepsia.
          <year>2005</year>
<volume>46</volume>
<issue>Suppl 7</issue>
<fpage>22</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2005.00305.x</pub-id>
<pub-id pub-id-type="pmid">16201992</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roll</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rudolf</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Royer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Massacrier</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SRPX2 mutations in disorders of language cortex and cognition</article-title>
<source/>Hum Mol Genet
          <year>2006</year>
<volume>15</volume>
<fpage>1195</fpage>
<lpage>1207</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddl035</pub-id>
<pub-id pub-id-type="pmid">16497722</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Royer-Zemmour</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ponsole-Lenfant</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Roll</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Leveque</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Massacrier</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR</article-title>
<source/>Hum Mol Genet
          <year>2008</year>
<volume>17</volume>
<fpage>3617</fpage>
<lpage>3630</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddn256</pub-id>
<pub-id pub-id-type="pmid">18718938</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<mixed-citation publication-type="other">Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76 Pt A:27-50. doi:10.1016/j.neuropharm.2013.07.004.</mixed-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update</article-title>
<source/>Pharmacol Rep
          <year>2015</year>
<volume>67</volume>
<fpage>195</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharep.2014.09.004</pub-id>
<pub-id pub-id-type="pmid">25712639</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deininger</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Trautmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Magdolen</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Luther</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schluesener</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Meyermann</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor</article-title>
<source/>Neurosci Lett
          <year>2002</year>
<volume>324</volume>
<fpage>80</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/s0304-3940(02)00168-4</pub-id>
<pub-id pub-id-type="pmid">11983300</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Van Nostrand</surname>
<given-names>WE</given-names>
</name>
</person-group>
<article-title>Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<fpage>19054</fpage>
<lpage>19061</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M301398200</pub-id>
<pub-id pub-id-type="pmid">12754271</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Lue</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Beach</surname>
<given-names>TG</given-names>
</name>
</person-group>
<article-title>Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains</article-title>
<source/>Brain Res
          <year>2002</year>
<volume>926</volume>
<fpage>69</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1016/s0006-8993(01)03298-x</pub-id>
<pub-id pub-id-type="pmid">11814408</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pocchiari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Puopolo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Croes</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Budka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gelpi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies</article-title>
<source/>Brain : a journal of neurology
          <year>2004</year>
<volume>127</volume>
<fpage>2348</fpage>
<lpage>2359</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awh249</pub-id>
<pub-id pub-id-type="pmid">15361416</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dendrou</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Fugger</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Friese</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Immunopathology of multiple sclerosis</article-title>
<source/>Nat Rev Immunol
          <year>2015</year>
<volume>15</volume>
<fpage>545</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="doi">10.1038/nri3871</pub-id>
<pub-id pub-id-type="pmid">26250739</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Washington</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Burton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Todd</surname>
<given-names>RF</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Newman</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Dragovic</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dore-Duffy</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis</article-title>
<source/>Ann Neurol
          <year>1994</year>
<volume>35</volume>
<fpage>89</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410350114</pub-id>
<pub-id pub-id-type="pmid">7506877</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dore-Duffy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Washington</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dragovic</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis</article-title>
<source/>Adv Exp Med Biol
          <year>1993</year>
<volume>331</volume>
<fpage>243</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-4615-2920-0_38</pub-id>
<pub-id pub-id-type="pmid">8333339</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gveric</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hanemaaijer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Newcombe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Lent</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Sier</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Cuzner</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage</article-title>
<source/>Brain.
          <year>2001</year>
<volume>124</volume>
<fpage>1978</fpage>
<lpage>1988</lpage>
<pub-id pub-id-type="doi">10.1093/brain/124.10.1978</pub-id>
<pub-id pub-id-type="pmid">11571216</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Archinti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Britto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Eden</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Furlan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Degryse</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The urokinase receptor in the central nervous system</article-title>
<source/>CNS Neurol Disord Drug Targets
          <year>2011</year>
<volume>10</volume>
<fpage>271</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.2174/187152711794480393</pub-id>
<pub-id pub-id-type="pmid">20874700</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cox</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Bowden</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lechner-Scott</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation</article-title>
<source/>Multiple sclerosis (Houndmills, Basingstoke, England)
          <year>2013</year>
<volume>19</volume>
<fpage>1268</fpage>
<lpage>1274</lpage>
<pub-id pub-id-type="doi">10.1177/1352458513475493</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Washington</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Becher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Balabanov</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Antel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dore-Duffy</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Expression of the activation marker urokinase plasminogen-activator receptor in cultured human central nervous system microglia</article-title>
<source/>J Neurosci Res
          <year>1996</year>
<volume>45</volume>
<fpage>392</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1002/(sici)1097-4547(19960815)45:4&lt;392::Aid-jnr8&gt;3.0.Co;2-4</pub-id>
<pub-id pub-id-type="pmid">8872899</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teesalu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hinkkanen</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Vaheri</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice</article-title>
<source/>Am J Pathol
          <year>2001</year>
<volume>159</volume>
<fpage>2227</fpage>
<lpage>2237</lpage>
<pub-id pub-id-type="doi">10.1016/s0002-9440(10)63073-8</pub-id>
<pub-id pub-id-type="pmid">11733372</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Campion</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sidenius</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Docagne</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation</article-title>
<source/>Glia.
          <year>2009</year>
<volume>57</volume>
<fpage>1802</fpage>
<lpage>1814</lpage>
<pub-id pub-id-type="doi">10.1002/glia.20892</pub-id>
<pub-id pub-id-type="pmid">19459212</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>East</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pryce</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lijnen</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Cuzner</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Gveric</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis</article-title>
<source/>Am J Pathol
          <year>2005</year>
<volume>167</volume>
<fpage>545</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1016/s0002-9440(10)62996-3</pub-id>
<pub-id pub-id-type="pmid">16049338</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gur-Wahnon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mizrachi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maaravi-Pinto</surname>
<given-names>FY</given-names>
</name>
<name>
<surname>Lourbopoulos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grigoriadis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Higazi</surname>
<given-names>AA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The plasminogen activator system: involvement in central nervous system inflammation and a potential site for therapeutic intervention</article-title>
<source/>J Neuroinflammation
          <year>2013</year>
<volume>10</volume>
<fpage>124</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-10-124</pub-id>
<pub-id pub-id-type="pmid">24120085</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gobel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pankratz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Asaridou</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Bittner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Merker</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells</article-title>
<source/>Nat Commun
          <year>2016</year>
<volume>7</volume>
<fpage>11626</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms11626</pub-id>
<pub-id pub-id-type="pmid">27188843</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brew</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Update on HIV dementia and HIV-associated neurocognitive disorders</article-title>
<source/>Current neurology and neuroscience reports
          <year>2014</year>
<volume>14</volume>
<fpage>468</fpage>
<pub-id pub-id-type="doi">10.1007/s11910-014-0468-2</pub-id>
<pub-id pub-id-type="pmid">24938216</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cinque</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nebuloni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Santovito</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Gisslen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hagberg</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations</article-title>
<source/>Ann Neurol
          <year>2004</year>
<volume>55</volume>
<fpage>687</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.1002/ana.20076</pub-id>
<pub-id pub-id-type="pmid">15122709</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidenius</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nebuloni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zerbi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Gisslen</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease</article-title>
<source/>J Neuroimmunol
          <year>2004</year>
<volume>157</volume>
<fpage>133</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2004.08.038</pub-id>
<pub-id pub-id-type="pmid">15579290</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidenius</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sier</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Ullum</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Lepri</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection</article-title>
<source/>Blood.
          <year>2000</year>
<volume>96</volume>
<fpage>4091</fpage>
<lpage>4095</lpage>
<pub-id pub-id-type="doi">10.1182/blood.V96.13.4091</pub-id>
<pub-id pub-id-type="pmid">11110678</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Idro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>CR</given-names>
</name>
</person-group>
<article-title>Pathogenesis, clinical features, and neurological outcome of cerebral malaria</article-title>
<source/>The Lancet Neurology
          <year>2005</year>
<volume>4</volume>
<fpage>827</fpage>
<lpage>840</lpage>
<pub-id pub-id-type="doi">10.1016/s1474-4422(05)70247-7</pub-id>
<pub-id pub-id-type="pmid">16297841</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fauser</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Deininger</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kremsner</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Magdolen</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Luther</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Meyermann</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria</article-title>
<source/>J Neuroimmunol
          <year>2000</year>
<volume>111</volume>
<fpage>234</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1016/s0165-5728(00)00368-4</pub-id>
<pub-id pub-id-type="pmid">11063844</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piguet</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Da Laperrousaz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vesin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tacchini-Cottier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Senaldi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grau</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice</article-title>
<source/>Infect Immun
          <year>2000</year>
<volume>68</volume>
<fpage>3822</fpage>
<lpage>3829</lpage>
<pub-id pub-id-type="doi">10.1128/iai.68.7.3822-3829.2000</pub-id>
<pub-id pub-id-type="pmid">10858190</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wassmer</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Combes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Grau</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Pathophysiology of cerebral malaria: role of host cells in the modulation of cytoadhesion</article-title>
<source/>Ann N Y Acad Sci
          <year>2003</year>
<volume>992</volume>
<fpage>30</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.2003.tb03135.x</pub-id>
<pub-id pub-id-type="pmid">12794044</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khor</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gardet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xavier</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Genetics and pathogenesis of inflammatory bowel disease</article-title>
<source/>Nature.
          <year>2011</year>
<volume>474</volume>
<fpage>307</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1038/nature10209</pub-id>
<pub-id pub-id-type="pmid">21677747</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caobelli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Quartuccio</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Familiari</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Altini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Castello</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of molecular imaging in the management of patients affected by inflammatory bowel disease: state-of-the-art</article-title>
<source/>World journal of radiology
          <year>2016</year>
<volume>8</volume>
<fpage>829</fpage>
<lpage>845</lpage>
<pub-id pub-id-type="doi">10.4329/wjr.v8.i10.829</pub-id>
<pub-id pub-id-type="pmid">27843542</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catalano</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Maccioni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lauri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Auletta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dierckx</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Signore</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Hybrid imaging in Crohn’s disease: from SPECT/CT to PET/MR and new image interpretation criteria</article-title>
<source/>Q J Nucl Med Mol Imaging
          <year>2018</year>
<volume>62</volume>
<fpage>40</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.23736/s1824-4785.17.03053-9</pub-id>
<pub-id pub-id-type="pmid">29191001</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meijer</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Mieremet-Ooms</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sier</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>van Hogezand</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Lamers</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Hommes</surname>
<given-names>DW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn’s disease</article-title>
<source/>Inflamm Bowel Dis
          <year>2009</year>
<volume>15</volume>
<fpage>84</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1002/ibd.20581</pub-id>
<pub-id pub-id-type="pmid">18634035</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birch</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dhaliwal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Optical molecular imaging of inflammatory cells in interventional medicine-an emerging strategy</article-title>
<source/>Frontiers in oncology
          <year>2019</year>
<volume>9</volume>
<fpage>882</fpage>
<pub-id pub-id-type="doi">10.3389/fonc.2019.00882</pub-id>
<pub-id pub-id-type="pmid">31572676</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Bruin</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Crama-Bohbouth</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Verspaget</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Verheijen</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Dooijewaard</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Weterman</surname>
<given-names>IT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Plasminogen activators in the intestine of patients with inflammatory bowel disease</article-title>
<source/>Thromb Haemost
          <year>1988</year>
<volume>60</volume>
<fpage>262</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1055/s-0038-1647042</pub-id>
<pub-id pub-id-type="pmid">3146142</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jong</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Porte</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Knot</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Verheijen</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Dees</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces</article-title>
<source/>Gut.
          <year>1989</year>
<volume>30</volume>
<fpage>188</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1136/gut.30.2.188</pub-id>
<pub-id pub-id-type="pmid">2495239</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ravi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sitaraman</surname>
<given-names>SV</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases in inflammatory bowel disease: boon or a bane?</article-title>
<source/>Inflamm Bowel Dis
          <year>2007</year>
<volume>13</volume>
<fpage>97</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1002/ibd.20011</pub-id>
<pub-id pub-id-type="pmid">17206645</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laerum</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Illemann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Skarstein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Helgeland</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ovrebo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dano</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Crohn’s disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons</article-title>
<source/>Am J Gastroenterol
          <year>2008</year>
<volume>103</volume>
<fpage>2350</fpage>
<lpage>2358</lpage>
<pub-id pub-id-type="doi">10.1111/j.1572-0241.2008.01930.x</pub-id>
<pub-id pub-id-type="pmid">18844621</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genua</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D’Alessio</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cibella</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gandelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sala</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Correale</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation</article-title>
<source/>Gut.
          <year>2015</year>
<volume>64</volume>
<fpage>589</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1136/gutjnl-2013-305933</pub-id>
<pub-id pub-id-type="pmid">24848264</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Saurer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schenk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dickgreber</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>CX3CR1 defines functionally distinct intestinal mononuclear phagocyte subsets which maintain their respective functions during homeostatic and inflammatory conditions</article-title>
<source/>Eur J Immunol
          <year>2011</year>
<volume>41</volume>
<fpage>773</fpage>
<lpage>779</lpage>
<pub-id pub-id-type="doi">10.1002/eji.201040965</pub-id>
<pub-id pub-id-type="pmid">21341263</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Na</surname>
<given-names>YR</given-names>
</name>
<name>
<surname>Stakenborg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seok</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Matteoli</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD</article-title>
<source/>Nat Rev Gastroenterol Hepatol
          <year>2019</year>
<volume>16</volume>
<fpage>531</fpage>
<lpage>543</lpage>
<pub-id pub-id-type="doi">10.1038/s41575-019-0172-4</pub-id>
<pub-id pub-id-type="pmid">31312042</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yousif</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Minopoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bifulco</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ingangi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Di Carluccio</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Merlino</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr peptide generates a potent inhibitor of trans-endothelial migration of monocytes</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0126172</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0126172</pub-id>
<pub-id pub-id-type="pmid">25938482</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genua</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ingangi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Fonteyne</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Piontini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yousif</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Merlino</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment with a urokinase receptor-derived cyclized peptide improves experimental colitis by preventing monocyte recruitment and macrophage polarization</article-title>
<source/>Inflamm Bowel Dis
          <year>2016</year>
<volume>22</volume>
<fpage>2390</fpage>
<lpage>2401</lpage>
<pub-id pub-id-type="doi">10.1097/mib.0000000000000896</pub-id>
<pub-id pub-id-type="pmid">27537052</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Receptor-targeted nanoparticles for in vivo imaging of breast cancer</article-title>
<source/>Clinical cancer research.
          <year>2009</year>
<volume>15</volume>
<fpage>4722</fpage>
<lpage>4732</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-08-3289</pub-id>
<pub-id pub-id-type="pmid">19584158</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles</article-title>
<source/>Gastroenterology
          <year>2009</year>
<volume>136</volume>
<fpage>1514</fpage>
<lpage>25.e2</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2009.01.006</pub-id>
<pub-id pub-id-type="pmid">19208341</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdalla</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Karna</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sajja</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy</article-title>
<source/>Journal of controlled release
          <year>2011</year>
<volume>149</volume>
<fpage>314</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1016/j.jconrel.2010.10.030</pub-id>
<pub-id pub-id-type="pmid">21047537</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Overbey</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Watkinson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Giblin</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Synthesis and characterization of an (111)in-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR)</article-title>
<source/>Bioconjug Chem
          <year>2009</year>
<volume>20</volume>
<fpage>888</fpage>
<lpage>894</lpage>
<pub-id pub-id-type="doi">10.1021/bc800433y</pub-id>
<pub-id pub-id-type="pmid">19354275</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gonzalo</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Photoacoustic and fluorescence image-guided surgery using a multifunctional targeted nanoprobe</article-title>
<source/>Ann Surg Oncol
          <year>2014</year>
<volume>21</volume>
<fpage>1602</fpage>
<lpage>1609</lpage>
<pub-id pub-id-type="doi">10.1245/s10434-014-3541-9</pub-id>
<pub-id pub-id-type="pmid">24554061</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Staley</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Satpathy</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer</article-title>
<source/>ACS Nano
          <year>2013</year>
<volume>7</volume>
<fpage>2078</fpage>
<lpage>2089</lpage>
<pub-id pub-id-type="doi">10.1021/nn3043463</pub-id>
<pub-id pub-id-type="pmid">23402593</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sajja</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>AI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection</article-title>
<source/>Theranostics.
          <year>2013</year>
<volume>4</volume>
<fpage>106</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.7150/thno.7409</pub-id>
<pub-id pub-id-type="pmid">24396518</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with (99 m)Tc-Hynic-PEG-AE105</article-title>
<source/>Oncol Lett
          <year>2015</year>
<volume>10</volume>
<fpage>2253</fpage>
<lpage>2258</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2015.3504</pub-id>
<pub-id pub-id-type="pmid">26622829</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nedergaard</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Brandt-Larsen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Skovgaard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jørgensen</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Michaelsen</surname>
<given-names>SR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Urokinase-type plasminogen activator receptor as a potential PET biomarker in glioblastoma</article-title>
<source/>Journal of Nuclear Medicine.
          <year>2016</year>
<volume>57</volume>
<fpage>272</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.115.161703</pub-id>
<pub-id pub-id-type="pmid">26429955</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juhl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ploug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kjaer</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Peptide-based optical uPAR imaging for surgery: in vivo testing of ICG-Glu-Glu-AE105</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<fpage>e0147428</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0147428</pub-id>
<pub-id pub-id-type="pmid">26828431</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Juhl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Charabi</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>15407</fpage>
<lpage>15419</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.14282</pub-id>
<pub-id pub-id-type="pmid">28039488</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juhl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rubek</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Karnov</surname>
<given-names>KKS</given-names>
</name>
<name>
<surname>von Buchwald</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kjaer</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<source/>Oncotarget
          <year>2019</year>
<volume>10</volume>
<fpage>6308</fpage>
<lpage>6316</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.27220</pub-id>
<pub-id pub-id-type="pmid">31695839</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurbegovic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Juhl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Leth</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular targeted NIR-II probe for image-guided brain tumor surgery</article-title>
<source/>Bioconjug Chem
          <year>2018</year>
<volume>29</volume>
<fpage>3833</fpage>
<lpage>3840</lpage>
<pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00669</pub-id>
<pub-id pub-id-type="pmid">30296054</pub-id>
</element-citation>
</ref>
<ref id="CR211">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LeBeau</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Duriseti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Pepin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer</article-title>
<source/>Cancer Res
          <year>2013</year>
<volume>73</volume>
<fpage>2070</fpage>
<lpage>2081</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.Can-12-3526</pub-id>
<pub-id pub-id-type="pmid">23400595</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LeBeau</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Sevillano</surname>
<given-names>N</given-names>
</name>
<name>
<surname>King</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Duriseti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Craik</surname>
<given-names>CS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance</article-title>
<source/>Theranostics.
          <year>2014</year>
<volume>4</volume>
<fpage>267</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.7150/thno.7323</pub-id>
<pub-id pub-id-type="pmid">24505235</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boonstra</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Van Driel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Keereweer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Prevoo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stammes</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Baart</surname>
<given-names>VM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer</article-title>
<source/>Oral Oncol
          <year>2017</year>
<volume>66</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.oraloncology.2016.12.026</pub-id>
<pub-id pub-id-type="pmid">28249642</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<label>214.</label>
<mixed-citation publication-type="other">Boonstra MC, van Driel PB, van Willigen DM, Stammes MA, Prevoo HA, Tummers QR, et al. uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery. Oncotarget. 2015;6:14260-14273. doi:10.18632/oncotarget.3680.</mixed-citation>
</ref>
<ref id="CR215">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Appella</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The growth factor module of urokinase is the binding sequence for its receptor</article-title>
<source/>Ann N Y Acad Sci
          <year>1987</year>
<volume>511</volume>
<fpage>192</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1987.tb36247.x</pub-id>
<pub-id pub-id-type="pmid">2830824</pub-id>
</element-citation>
</ref>
<ref id="CR216">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lwin</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Bouvet</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic</article-title>
<source/>Expert Rev Anticancer Ther
          <year>2018</year>
<volume>18</volume>
<fpage>651</fpage>
<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1080/14737140.2018.1477593</pub-id>
<pub-id pub-id-type="pmid">29768067</pub-id>
</element-citation>
</ref>
<ref id="CR217">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodson</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>High-affinity urokinase receptor antagonists identified with bacteriophage peptide display</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1994</year>
<volume>91</volume>
<fpage>7129</fpage>
<lpage>7133</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.91.15.7129</pub-id>
<pub-id pub-id-type="pmid">8041758</pub-id>
</element-citation>
</ref>
<ref id="CR218">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ploug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Østergaard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gårdsvoll</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kovalski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Holst-Hansen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation</article-title>
<source/>Biochemistry
          <year>2001</year>
<volume>40</volume>
<fpage>12157</fpage>
<lpage>12168</lpage>
<pub-id pub-id-type="doi">10.1021/bi010662g.</pub-id>
<pub-id pub-id-type="pmid">11580291</pub-id>
</element-citation>
</ref>
<ref id="CR219">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>El Ali</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Binderup</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pfeifer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging</article-title>
<source/>Nucl Med Biol
          <year>2014</year>
<volume>41</volume>
<fpage>290</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.1016/j.nucmedbio.2013.12.007</pub-id>
<pub-id pub-id-type="pmid">24533988</pub-id>
</element-citation>
</ref>
<ref id="CR220">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hosseini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jørgensen</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Kjaer</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improved PET imaging of uPAR expression using new (64)cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies</article-title>
<source/>Theranostics.
          <year>2013</year>
<volume>3</volume>
<fpage>618</fpage>
<lpage>632</lpage>
<pub-id pub-id-type="doi">10.7150/thno.6810</pub-id>
<pub-id pub-id-type="pmid">24052804</pub-id>
</element-citation>
</ref>
<ref id="CR221">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>ZB</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ploug</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET</article-title>
<source/>Clinical Cancer Research
          <year>2008</year>
<volume>14</volume>
<fpage>4758</fpage>
<lpage>4766</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-07-4434</pub-id>
<pub-id pub-id-type="pmid">18676745</pub-id>
</element-citation>
</ref>
<ref id="CR222">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Østergaard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Jørgensen</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Juhl</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion</article-title>
<source/>J Nuclear Medicine
          <year>2012</year>
<volume>53</volume>
<fpage>138</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.2967/jnumed.110.083386</pub-id>
</element-citation>
</ref>
<ref id="CR223">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skovgaard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Persson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kjaer</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Imaging of prostate cancer using urokinase-type plasminogen activator receptor PET</article-title>
<source/>PET Clin
          <year>2017</year>
<volume>12</volume>
<fpage>243</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1016/j.cpet.2016.12.005</pub-id>
<pub-id pub-id-type="pmid">28267457</pub-id>
</element-citation>
</ref>
<ref id="CR224">
<label>224.</label>
<mixed-citation publication-type="other">Pedersen SF, Petersen LR, Skovgaard DC, Persson M, Johannesen HH, Brandt-Larsen M, et al. Feasibility of 64Cu-DOTA-AE105 for arterial wall in vivo PET of the urokinase-plasminogen-activator-receptor (uPAR). J Nucl Med. 2016;57:1632.</mixed-citation>
</ref>
<ref id="CR225">
<label>225.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mengele</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Napieralski</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Magdolen</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Reuning</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Gkazepis</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1</article-title>
<source/>Expert Rev Mol Diagn
          <year>2010</year>
<volume>10</volume>
<fpage>1051</fpage>
<lpage>1067</lpage>
<pub-id pub-id-type="doi">10.1586/erm.10.71</pub-id>
<pub-id pub-id-type="pmid">21080821</pub-id>
</element-citation>
</ref>
<ref id="CR226">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duriseti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Hostetter</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>LeBeau</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Craik</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<fpage>26878</fpage>
<lpage>26888</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.077677</pub-id>
<pub-id pub-id-type="pmid">20501655</pub-id>
</element-citation>
</ref>
<ref id="CR227">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Camp</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Somcio</surname>
<given-names>RJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice</article-title>
<source/>Cancer Res
          <year>2005</year>
<volume>65</volume>
<fpage>7775</fpage>
<lpage>7781</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.Can-05-0946</pub-id>
<pub-id pub-id-type="pmid">16140945</pub-id>
</element-citation>
</ref>
<ref id="CR228">
<label>228.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabbani</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Ateeq</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Arakelian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Valentino</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Dauffenbach</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo</article-title>
<source/>Neoplasia.
          <year>2010</year>
<volume>12</volume>
<fpage>778</fpage>
<lpage>788</lpage>
<pub-id pub-id-type="doi">10.1593/neo.10296</pub-id>
<pub-id pub-id-type="pmid">20927316</pub-id>
</element-citation>
</ref>
<ref id="CR229">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahmood</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Arakelian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Tanvir</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mazar</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Rabbani</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions</article-title>
<source/>Bone Res
          <year>2020</year>
<volume>8</volume>
<fpage>18</fpage>
<pub-id pub-id-type="doi">10.1038/s41413-020-0094-3</pub-id>
<pub-id pub-id-type="pmid">32337090</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>